IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	Mind Medicine, Inc.	Confirmation No.:
Serial No.:	17/833,829	Group No.:
Filing or 371(c) Date:	6 June 2022	Examiner:
Entitled: CONTROLLI	NG EFFECTS AFTER 5HT2A AG	GONISTS ADMINISTRATION

THIRD-PARTY PRE-ISSUANCE SUBMISSION

Examiner:

The following documents, which are also identified in the Form PTO/SB/429 filed herewith, are submitted for your consideration as being of potential relevance to the examination of the present application:

- 1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
- VALERIANI (2015) "Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substancerelated psychotic symptoms" Human Psychopharmacology: Clinical and Experimental. 30:249-254.
- PHARMBOY (2013) "Cheating Hofmann LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL:

https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

- GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: <u>https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109</u>
- MAHATMAGANJA (2007) "Mood Stabilizers Cancel Trip Mushrooms, Olanzapine (Zyprexa) & Fluoxetine (Prozac)" Retrieved from 05 September 2007. URL: <u>https://web.archive.org/web/20070905190454/https://erowid.org/experiences/exp.php?ID=44850</u>
- BIGWOOD (1982) "Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of *Psilocybe cubensis* (earle) singer" Journal of Ethnopharmacology. 5(3):287-291.

- 7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: <u>https://web.archive.org/web/20200928082744/https://www.psychedelicpassage.com/psychedelicdosage-guide-how-much-of-each-substance-to-take/</u>
- FDA (2016) "NUPLAZID (PIMAVANSERIN): HIGHLIGHTS OF PRESCRIBING INFORMATION" URL: <u>https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf</u>
- 9. NIMH (2021) "Understanding Psychosis" Retrieved 13 May 2021. URL: <u>https://web.archive.org/web/20210503133654/https://www.nimh.nih.gov/health/publications/und</u> <u>erstanding-psychosis/</u>

Attached hereto is a claim chart providing a concise description of the relevance of each reference in the document list to the elements of the presently pending claims.

U.S.S.N. 17/833,829	References
Pending Claims	
1. A composition for treating an individual while reducing acute effects, comprising	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
effective amounts of a psychedelic drug and a duration shortening	From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):
agent.	R_{3} R_{4} R_{5} R_{7} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2}
	wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;
	wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;
	wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and
	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;
	wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and
	(ii) a 5-HT2A receptor antagonist;
	for use as a medicament."
	From claim 3 "The combination product for use according to anyone of claims 1 -2 wherein the compound described by formula (I) is selected from the group consisting of N,N-

	 dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine." From claim 4 "The combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, Pimavanserin, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects
	caused by a compound described by formula (1)."
2. The composition of claim 1, wherein said psychedelic drug is a 5HT2A agonist chosen from the group	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From claim 1 "A pharmaceutical combination product
consisting of LSD, psilocybin, psilocin, mescaline, 5-methoxy-	comprising: compound described by the following formula (I):
N,N- dimethyltryptamine (5- MeO-DMT), dimethyltryptamine (DMT), 2,5-dimethoxy- 4-iodoamphetamine (DOI), 2,5-dimethoxy- 4-bromoamphetamie (DOB), salts thereof, tartrates thereof, solvates thereof, isomers thereof, deuterated forms thereof, analogs thereof, and	$\begin{array}{c} R_{3} \\ R_{4} \\ R_{5} \\ R_{5} \\ R_{5} \\ R_{5} \\ R_{5} \\ R_{5} \\ R_{1} \\ R_{2} \\ R_{2} \\ R_{3} \\ R_{2} \\ R_{3} \\ R_{4} \\ R_{5} \\$
homologues thereof.	n-propyl, allyl and isopropyl;

	wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;
	wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and
	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;
	wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and
	(ii) a 5-HT2A receptor antagonist;
	for use as a medicament."
	From claim 3 "The combination product for use according to anyone of claims 1 -2 wherein the compound described by formula (I) is selected from the group consisting of N , N - dimethyltryptamine , 5 - methoxy-N , N - dimethyltryptamine , N,N- diethyltryptamine, N,N-dipropyltryptamine and N,N- diisopropyltryptamine."
	From claim 4 "The combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, Pimavanserin , Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK- 215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150."
	From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
3. The composition of claim 1, wherein said psychedelic drug is present in an amount	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)

that provides an effect for at least 2 hours.

From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):



wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;

wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and**

(ii) a 5-HT2A receptor antagonist;

for use as a medicament."

From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula** (I) is selected from the group consisting of N,N**dimethyltryptamine**, **5**-methoxy-N,N-**dimethyltryptamine**, N,N**diethyltryptamine**, N,N-**dipropyltryptamine** and N,N**diisopropyltryptamine**."

From claim 4 "The combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is selected from the group consisting of Methiothepin, Ritanserin,

Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, Pimavanserin , Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK- 215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150."
From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
From page 29 "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise 0.5 -1000 mg of a compound described by formula (I) and/or 0.5 - 1000 mg of a 5- HT2A receptor antagonist."
2. VALERIANI (2015) "Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms" Human Psychopharmacology: Clinical and Experimental. 30:249-254.
From page 250 "In most cases, users reported here to ingest olanzapine at relatively small dosages, usually ranging from 5 to 10 mg once a day for just a few days as a "terminator"/"modulator" of unwanted NPS psychedelic effects."
From page 251 "Most online reports about olanzapine were here related to its use as a short-term, self-prescribed treatment for the psychedelic crises/"bad trips." Symptoms of psychedelic crises usually last a few hours, depending on the drug taken and dose ingested (Mangot, 2013). Indeed, SC's effects may last 1–4 h (Hoyte et al., 2012); tryptamines' effects 2–6 h (Hallock et al., 2013); lysergic acid diethylamide [LSD] 6–14 h (Krebs and Johansen, 2013); and mescaline 8–16 h (Trachsel, 2012)."
From page 251 "There are already published data showing the effectiveness of olanzapine and, in general, of second-generation antipsychotics (SGA), as first-line treatments in psychotic disorders

induced by drugs such as cannabis (Bersani et al., 2002a, 2002b; Sevy et al., 2011) and cocaine (Testa et al., 2013). Compared with first-generation antipsychotics (FGA), SGA may present with some advantages while treating drug-induced psychosis, including the following: (i) SGA induce fewer/no extrapyramidal symptoms (Ohno et al., 2013); (ii) SGA quickly dissociate from D2 receptors, unlike FGA/haloperidol, and hence may seem to be less associated with dysphoria and interference with drug reward anticipation/craving (Juckel et al., 2006); (iii) SGA seem more effective in the treatment of negative symptoms (Buchanan et al., 2005), alter positively mood (McIntyre et al., 2004), and have a positive impact on cognition (Bersani et al., 2011); and (iv) SGA act as antagonists of 5HT2A receptor, which is the main target of most hallucinogenic drugs (Potvin et al., 2003). From this point of view, both clozapine and olanzapine may present with a distinct advantage in reducing drug-induced psychotic symptoms (Murthy and Chand, 2012)."

5. MAHATMAGANJA (2007) "Mood Stabilizers Cancel Trip Mushrooms, Olanzapine (Zyprexa) & Fluoxetine (Prozac)" Retrieved from 05 September 2007. https://web.archive.org/web/20070905190454/https://erowid.org/ex

periences/exp.php?ID=44850



"For the past 2 months I have been taking 6 mg Zyprexa and 25 mg Prozac under the name Symbyax daily. I have taken mushrooms before, but never while on Symbyax. **Tonight I ate one gram of powerful mushrooms with no effects after 4 hours.** I did some research and found a report of a person **eating 8 g of cubensis mushrooms while on Zyprexa with no effects**"

6. BIGWOOD (1982) "Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (earle) singer" Journal of Ethnopharmacology. 5(3):287-291.

From page 289

The dry tion of f	e dry weight variation of psilocybin and psilocin levels in <i>Psilocybe cubensis</i> as a func- on of flush number (quantified by HPLC)					
Flush	Miniculture	No. 1	Miniculture	No. 2	Miniculture	No. 3
No.	Psilocybin (mg/g)	Psilocin (mg/g)	Psilocybin (mg/g)	Psilocin (mg/g)	Psilocybin (mg/g)	Psilocir (mg/g)
1	8.3	0.5	5.1	0	7.6	0
2	6.5	1.5	7.3	0	6.2	0
3	13.3	1.0	4.7	1.7	5.3	0.9
4	4.8	2.6	3.7	2.9	3.2	1.8
5	-	-	5.2	2.2	6.7	1.7
6	6.8	0.5	-		_	

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL:

https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit."

7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: <u>https://web.archive.org/web/20200928082744/https://www.psyched</u> <u>elicpassage.com/psychedelic-dosage-guide-how-much-of-each-</u> <u>substance-to-take/</u>

"Lysergic Acid Diethylamide (LSD): Recommended Dosage: $50 - 150 \ \mu g$ (micrograms) per individual, $200 + \ \mu g$ in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 \ \mu g per tab.**"

4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: <u>https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109</u>

	From paragraph 5 " Quetiapine has antagonist actions at 5- HT2A receptors , one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
4. The composition of claim 3, wherein said psychedelic drug is	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
present in an amount chosen from the group consisting of 0.01-1 mg	From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):
psilocybin, 100-800 mg mescaline, 20-100 mg DMT, 0.1-5 mg DOI, and 0.1-5 mg DOB.	$R_3 \qquad R_4 \qquad R_5 \qquad R_7 \qquad R_1 \qquad R_2 \qquad R_2 \qquad R_2 \qquad R_1 \qquad R_2 \qquad R_2 \qquad R_2 \qquad R_1 \qquad R_2 $
	wherein R1 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
	wherein R2 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
	wherein R3 is selected from the group consisting of hydrogen , methoxy, methyl, hydroxy and a halogen; and
	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;
	wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and
	(ii) a 5-HT2A receptor antagonist;
	for use as a medicament."

From claim 3 "The combination product for use according to anyone of claims 1 -2 wherein the compound described by formula (I) is selected from the group consisting of N,Ndimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,Ndiethyltryptamine, N,N-dipropyltryptamine and N,Ndiisopropyltryptamine." From page 29 "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5** -1000 mg of a compound described by formula (I) and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist." 2. VALERIANI (2015) "Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms" Human Psychopharmacology: Clinical and Experimental. 30:249-254. From page 250 "In most cases, users reported here to ingest olanzapine at relatively small dosages, usually ranging from 5 to 10 mg once a day for just a few days as a "terminator"/"modulator" of unwanted NPS psychedelic effects." From page 251 "Most online reports about olanzapine were here related to its use as a short-term, self-prescribed treatment for the psychedelic crises/"bad trips." Symptoms of psychedelic crises usually last a few hours, depending on the drug taken and dose ingested (Mangot, 2013). Indeed, SC's effects may last 1-4 h (Hoyte et al., 2012); tryptamines' effects 2–6 h (Hallock et al., 2013); lysergic acid diethylamide [LSD] 6–14 h (Krebs and Johansen, 2013); and mescaline 8-16 h (Trachsel, 2012)." From **page 251** "There are already published data showing the effectiveness of olanzapine and, in general, of second-generation antipsychotics (SGA), as first-line treatments in psychotic disorders induced by drugs such as cannabis (Bersani et al., 2002a, 2002b; Sevy et al., 2011) and cocaine (Testa et al., 2013). Compared with first-generation antipsychotics (FGA), SGA may present with some advantages while treating drug-induced psychosis, including the following: (i) SGA induce fewer/no extrapyramidal symptoms (Ohno et al., 2013); (ii) SGA quickly dissociate from D2 receptors, unlike FGA/haloperidol, and hence may seem to be less associated with dysphoria and interference with drug reward

anticipation/craving (Juckel et al., 2006); (iii) SGA seem more effective in the treatment of negative symptoms (Buchanan et al., 2005), alter positively mood (McIntyre et al., 2004), and have a positive impact on cognition (Bersani et al., 2011); and (iv) SGA act as antagonists of 5HT2A receptor, which is the main target of most hallucinogenic drugs (Potvin et al., 2003). From this point of view, both clozapine and olanzapine may present with a distinct advantage in reducing drug-induced psychotic symptoms (Murthy and Chand, 2012)."
5. MAHATMAGANJA (2007) "Mood Stabilizers Cancel Trip Mushrooms, Olanzapine (Zyprexa) & Fluoxetine (Prozac)" Retrieved from 05 September 2007. https://web.archive.org/web/20070905190454/https://erowid.org/ex periences/exp.php?ID=44850
Mood Stabilizers Cancel Trip Mushrooms, Olanzapine (Zyprexa) & Fluoxetine(Prozac) by Mahatmaganja DOSE: 6 mg oral Pharms - Olanzapine (daily) 25 mg oral Pharms - Fluoxetine (daily) 1 g oral Mushrooms (driled)
For the past 2 months I have been taking 6 mg Zyprexa and 25 mg Prozac under the name Symbyax daily. I have taken mushrooms before, but never while on Symbyax. Tonight I ate one gram of powerful mushrooms with no effects after 4 hours. I did some research and found a report of a person eating 8 g of cubensis mushrooms while on Zyprexa with no effects "
5. BIGWOOD (1982) "Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (earle) singer" Journal of Ethnopharmacology. 5(3):287- 291.

The dry tion of f	e dry weight variation of psilocybin and psilocin levels in <i>Psilocybe cubensis</i> as a func- on of flush number (quantified by HPLC)					
Flush	Miniculture	No. 1	Miniculture	No. 2	Miniculture	No. 3
No.	Psilocybin (mg/g)	Psilocin (mg/g)	Psilocybin (mg/g)	Psilocin (mg/g)	Psilocybin (mg/g)	Psilocir (mg/g)
1	8.3	0.5	5.1	0	7.6	0
2	6.5	1.5	7.3	0	6.2	0
3	13.3	1.0	4.7	1.7	5.3	0.9
4	4.8	2.6	3.7	2.9	3.2	1.8
5	-	-	5.2	2.2	6.7	1.7
6	6.8	0.5	-		_	-

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL:

https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit."

7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: <u>https://web.archive.org/web/20200928082744/https://www.psyched</u> <u>elicpassage.com/psychedelic-dosage-guide-how-much-of-each-</u> <u>substance-to-take/</u>

"Lysergic Acid Diethylamide (LSD): Recommended Dosage: $50 - 150 \ \mu g$ (micrograms) per individual, $200 + \ \mu g$ in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 \ \mu g per tab.**"

4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: <u>https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109</u>

	From paragraph 5 " Quetiapine has antagonist actions at 5- HT2A receptors , one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
5. The composition of claim 1, wherein said duration shortening	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
receptor antagonist.	From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):
	R_{3} R_{4} R_{5} R_{7} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2}
	wherein R1 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
	wherein R2 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
	wherein R3 is selected from the group consisting of hydrogen , methoxy, methyl, hydroxy and a halogen; and
	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;
	wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and
	(ii) a 5-HT2A receptor antagonist;
	for use as a medicament."

6. The composition of claim 5, wherein said duration shortening agent is chosen from the group consisting of pimavanserin, salts thereof, analogs thereof, and homologs thereof.

1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)

From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):



wherein **R1** is selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl;

wherein **R2** is selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl;

wherein **R3** is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy;

wherein **R5** is selected from the group consisting of **deuterium** (2H) and protium (1H); and

(ii) a 5-HT2A receptor antagonist;

for use as a medicament."

From claim 4 "The combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone,

	 Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, Pimavanserin, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK- 215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
7. The composition of claim 6, wherein said pimavanserin is present in an amount of 1-100 mg.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I): $R_{3} \qquad R_{4} \qquad R_{5} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{5} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{5} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{5} \qquad R_{5$
	 n-propyl, allyl and isopropyl; wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

	wherein R4 is selected from the group consisting of hydrogen
	hydroxy phosphoryloxy and acetoxy.
	nyarozy, phosphorytozy and acciozy,
	wherein R5 is selected from the group consisting of deuterium
	(2H) and protium (1H); and
	(ii) a 5-HT2A receptor antagonist;
	for use as a medicament."
	From claim 4 "The combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, Pimavanserin , Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK- 215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-L-91 150."
	From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
	From page 29 "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise 0.5 -1000 mg of a compound described by formula (I) and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist ."
	8. FDA (2016) "NUPLAZID (PIMAVANSERIN): HIGHLIGHTS OF PRESCRIBING INFORMATION" URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318 lbl.pdf
	From page 1 "DOSAGE AND ADMINISTRATION: Recommended dose is 34 mg , taken orally as two 17 mg tablets once daily, without titration."
8. The composition of	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION
claim 1, wherein said	PRODUCT FOR THE TREATMENT OF NEUROLOGICAL

psychedelic drug and duration shortening agent are in dosage units chosen from the group consisting of separate dosage units, in the same dosage unit with the same release profiles, and in the same dosage unit with different release profiles.

AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)

From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):



wherein **R1** is selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl;

wherein **R2** is selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl;

wherein **R3** is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy;

wherein **R5** is selected from the group consisting of **deuterium** (2H) and protium (1H); and

(ii) a 5-HT2A receptor antagonist;

for use as a medicament."

From page 15 "The term "combination product' can refer to (i) a product comprised of two or more regulated components that are physically, chemically, or otherwise combined or mixed and produced as a single entity; (ii) two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products; (iii) a drug, device, or biological

	product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or (iv) any investigational drug, device, or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect."
9. A method of treating an individual with a psychedelic drug and	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
reducing or eliminating its acute duration of action, including the steps of: administering a	From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):
administering a psychedelic drug to the individual; administering a duration shortening and/or effect blocking agent to the individual; and shortening and/or reducing and/or eliminating the acute effects of the psychedelic drug.	R_{3} R_{4} R_{5} R_{1} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2}
	wherein R1 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
	wherein R2 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
	wherein R3 is selected from the group consisting of hydrogen , methoxy, methyl, hydroxy and a halogen; and
	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;

	wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and
	(ii) a 5-HT2A receptor antagonist;
	for use as a medicament."
	From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
10. The method of claim 9, wherein the duration shortening	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
agent is administered 1 minute to 24 hours after administering the psychedelic drug.	From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):
	R_{3} R_{4} R_{5} R_{1} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2}
	wherein R1 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
	wherein R2 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
	wherein R3 is selected from the group consisting of hydrogen , methoxy, methyl, hydroxy and a halogen; and
	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;

	wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and
	(ii) a 5-HT2A receptor antagonist;
	for use as a medicament."
	From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
	From page 32 "A compound described by formula (I) and a 5- HT2A receptor antagonist may be administered together or separately to an individual who suffers from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders.
	From page 32 "In a preferred embodiment, a compound described by formula (I) may be administered to an individual who is already being administered a 5-HT2A receptor antagonist and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. Conversely, in an alternative embodiment, a 5-HT2A receptor antagonist may be administered to an individual who is already being administered a compound described by formula (I) and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders."
11. The method of claim 9, wherein the psychedelic drug is a 5HT2A agonist chosen from the group consisting of LSD, psilocybin, psilocin, mescaline, 5-methoxy-	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):
N,N- dimethyltryptamine (5- MeO-DMT), dimethyltryptamine (DMT), 2,5-dimethoxy- 4-iodoamphetamine	

(DOI), 2,5-dimethoxy-4-bromoamphetamie (DOB), salts thereof, tartrates thereof, solvates thereof, isomers thereof, deuterated forms thereof, analogs thereof, and homologues thereof.



wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy;

wherein **R5** is selected from the group consisting of deuterium (2H) and protium (1H); and

(ii) a 5-HT2A receptor antagonist;

for use as a medicament."

From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula** (I) is selected from the group consisting of N,N**dimethyltryptamine**, **5**-methoxy-N,N-dimethyltryptamine, N,N**diethyltryptamine**, N,N-**dipropyltryptamine** and N,N**diisopropyltryptamine**."

From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."

12. The method of 1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION claim 9, wherein the PRODUCT FOR THE TREATMENT OF NEUROLOGICAL psychedelic drug is AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) administered in an amount that provides an From claim 1 "A pharmaceutical combination product effect for at least 2 comprising: compound described by the following formula (I): hours. R^5 wherein **R1** is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein **R2** is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein **R3** is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and wherein **R4** is selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5** is selected from the group consisting of deuterium (2H) and protium (1H); and (ii) a 5-HT2A receptor antagonist; for use as a medicament." From claim 3 "The combination product for use according to anyone of claims 1 -2 wherein the compound described by formula (I) is selected from the group consisting of N,Ndimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-

diethyltryptamine, N,N-dipropyltryptamine and N,N- diisopropyltryptamine."
From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
2. VALERIANI (2015) "Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms" Human Psychopharmacology: Clinical and Experimental. 30:249-254.
From page 250 "In most cases, users reported here to ingest olanzapine at relatively small dosages, usually ranging from 5 to 10 mg once a day for just a few days as a "terminator"/"modulator" of unwanted NPS psychedelic effects."
From page 251 "Most online reports about olanzapine were here related to its use as a short-term, self-prescribed treatment for the psychedelic crises/"bad trips." Symptoms of psychedelic crises usually last a few hours, depending on the drug taken and dose ingested (Mangot, 2013). Indeed, SC's effects may last 1–4 h (Hoyte et al., 2012); tryptamines' effects 2–6 h (Hallock et al., 2013); lysergic acid diethylamide [LSD] 6–14 h (Krebs and Johansen, 2013); and mescaline 8–16 h (Trachsel, 2012)."
From page 251 "There are already published data showing the effectiveness of olanzapine and, in general, of second-generation antipsychotics (SGA), as first-line treatments in psychotic disorders induced by drugs such as cannabis (Bersani et al., 2002a, 2002b; Sevy et al., 2011) and cocaine (Testa et al., 2013). Compared with first-generation antipsychotics (FGA), SGA may present with some advantages while treating drug-induced psychosis, including the following: (i) SGA induce fewer/no extrapyramidal symptoms (Ohno et al., 2013); (ii) SGA quickly dissociate from D2 receptors, unlike FGA/haloperidol, and hence may seem to be less associated with dysphoria and interference with drug reward anticipation/craving (Juckel et al., 2006); (iii) SGA seem more effective in the treatment of negative symptoms (Buchanan et al.,
2005), alter positively mood (McIntyre et al., 2004), and have a positive impact on cognition (Bersani et al., 2011); and (iv) SGA act as antagonists of 5HT2A receptor, which is the main target
of most hallucinogenic drugs (Potvin et al., 2003). From this point

of view, **both clozapine and olanzapine may present with a distinct advantage in reducing drug-induced psychotic symptoms** (Murthy and Chand, 2012)."

5. MAHATMAGANJA (2007) "Mood Stabilizers Cancel Trip Mushrooms, Olanzapine (Zyprexa) & Fluoxetine (Prozac)" Retrieved from 05 September 2007. https://web.archive.org/web/20070905190454/https://erowid.org/ex periences/exp.php?ID=44850



"For the past 2 months I have been taking 6 mg Zyprexa and 25 mg Prozac under the name Symbyax daily. I have taken mushrooms before, but never while on Symbyax. **Tonight I ate one gram of powerful mushrooms with no effects after 4 hours.** I did some research and found a report of a person **eating 8 g of cubensis mushrooms while on Zyprexa with no effects**"

6. BIGWOOD (1982) "Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (earle) singer" Journal of Ethnopharmacology. 5(3):287-291.

From page 289

```
TABLE 1
```

The dry weight variation of psilocybin and psilocin levels in *Psilocybe cubensis* as a function of flush number (quantified by HPLC)

Flush M No. Pr (r	Miniculture	Miniculture No. 1		No. 2	Miniculture No. 3	
	Psilocybin (mg/g)	Psilocin (mg/g)	Psilocybin (mg/g)	Psilocin (mg/g)	Psilocybin (mg/g)	Psilocin (mg/g)
1	8.3	0.5	5.1	0	7.6	0
2	6.5	1.5	7.3	0	6.2	0
3	13.3	1.0	4.7	1.7	5.3	0.9
4	4.8	2.6	3.7	2.9	3.2	1.8
5	-		5.2	2.2	6.7	1.7
6	6.8	0.5			_	_

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL:

https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

	DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
	T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
	T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
	T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
	T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	
	From paragran	h 25 "Consid	ering	how easy and smo	oth it felt
	coming down (a	albeit cutting (the LS	SD short) from the	psychedelic
	aspect of my tri	p using the Se	eroque	el, I would recomm	nend it to
	anyone, at least	to have as par	rt of a	psychedelic crisis	kit."
	7. LEVICH (20) Substance to Ta <u>https://web.arch</u> <u>elicpassage.com</u> <u>substance-to-tal</u>	20) "Psyched ke" Retrieved <u>tive.org/web/2</u> n/psychedelic- ke/	elic D 1 28 S 20200 -dosag	osage Guide: How eptember 2020. UI 928082744/https:// ge-guide-how-muc	Much of Each RL: <u>www.psyched</u> <u>h-of-each-</u>
	"Lysergic Acid 150 µg (microgr settingsthe mo which is an abso average sheet o containing abo	Diethylamide rams) per indi ost common fo orbent paper s of blotter pap ut 100 µg per	e (LSI avidua orm o soakec oer ha r tab. ²	D): Recommended 1, 200+ μg in highl f LSD comes on b l in a solution of L s about 100 unifo	Dosage: 50 – y supportive lotter paper, SD. An rm tabs
	4. GUZMAN (2 https://psychopl of-action-of-que	2016) "Mecha narmacologyi etiapine-2109	nism <u>nstitu</u>	of Action of Queti- te.com/publication	apine" URL: /mechanism-
	From paragrap HT2A receptor	bh 5 "Quetiap rs, one of the	oine h key p	as antagonist acti roperties of second	ons at 5-
	has higher affin	ity for 5-HT2	ve a n A rec	eptors than for D2	receptors [3]."
13. The method of	1. Int'l Pat. Doc	. No. WO/20	19/08	1764 "COMBINA	TION
claim 12, wherein the	PRODUCT FO	R THE TREA	TME	NT OF NEUROL	OGICAL
psychedelic drug is	AND/OR PSYC	CHIATRIC D	ISOR	DERS" (Published	02 May 2019)
administered in an	Erom alaim 1 "	1 nhormooo	rtiaal	combination nra	duct
the group consisting of	comprising: co	A pharmaced	ribed	combination prov I by the following	formula (I) [.]
0.01-1 mg LSD, 10-50	comprising. co	mpound dest		. Sy the following	101 muia (1).
mg psilocybin, 100-800					
mg mescaline, 20-100					
mg DMT, 0.1-5 mg					

DOI, and 0.1-5 mg DOB. R_3 5 5 н wherein **R1** is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein **R2** is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein **R3** is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and wherein **R4** is selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy; wherein **R5** is selected from the group consisting of deuterium (2H) and protium (1H); and (ii) a 5-HT2A receptor antagonist; for use as a medicament." From page 29 "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise 0.5 -1000 mg of a compound described by formula (I) and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist." From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."

2. VALERIANI (2015) "Olanzapine as the ideal "trip terminator"?
Analysis of online reports relating to antipsychotics' use and misuse
following occurrence of noval neuchoastive substance related
ionowing occurrence of novel psychoactive substance-related
psychotic symptoms" Human Psychopharmacology: Clinical and
Experimental. 30:249-254.
From page 250 "In most cases, users reported here to ingest
From page 250 in most cases, users reported here to ingest
olanzapine at relatively small dosages, usually ranging from 5 to
10 mg once a day for just a few days as a
"terminator"/"modulator" of unwanted NPS psychedelic
offacts "
cheets.
From page 251 "Most online reports about olanzapine were here
related to its use as a short-term, self-prescribed treatment for the
nevenhedelic crises "had tring" Symptoms of nevenhedelic crises
psychologic crises bad unps. Symptoms of psychologic crises
usually last a few nours, depending on the drug taken and dose
ingested (Mangot, 2013). Indeed, SC's effects may last 1–4 h (Hoyte
et al., 2012); tryptamines' effects 2–6 h (Hallock et al., 2013):
lyservic acid diethylamide [I SD] 6–14 h (Krebs and Johansen
(2012) and (2012)
2013); and mescaline 8–16 h (Trachsel, 2012)."
From page 251 "There are already published data showing the
effectiveness of olanzanine and in general of second-generation
antineveloptics (SGA) as first line treatments in neveloptic disorders
anupsycholics (SOA), as first-fille treatments in psycholic disorders
induced by drugs such as cannabis (Bersani et al., 2002a, 2002b;
Sevy et al., 2011) and cocaine (Testa et al., 2013). Compared with
first-generation antipsychotics (FGA). SGA may present with some
advantages while treating drug induced psychosis including the
advantages while treating drug-induced psychosis, including the
following: (1) SGA induce fewer/no extrapyramidal symptoms
(Ohno et al., 2013); (ii) SGA quickly dissociate from D2 receptors,
unlike FGA/haloperidol, and hence may seem to be less associated
with dysphoria and interference with drug reward
with dysphoria and interference with drug rewald
anticipation/craving (Juckel et al., 2006); (iii) SGA seem more
effective in the treatment of negative symptoms (Buchanan et al.,
2005), alter positively mood (McIntyre et al., 2004), and have a
positive impact on cognition (Rersani et al. 2011); and (iv) SCA
ast og antogonista of SHT3 A nogentan which is the main target
act as antagoinsts of 5m12A receptor, which is the main target
of most hallucinogenic drugs (Potvin et al., 2003). From this point
of view, both clozapine and olanzapine may present with a
distinct advantage in reducing drug-induced psychotic
symptoms (Muthy and Chand 2012) "
symptoms (wurmy and Chand, 2012).
5. MAHATMAGANJA (2007) "Mood Stabilizers Cancel Trip
Mushrooms Olanzaning (Zunrava) & Eluovating (Drozan)"
Musinoonis, Olanzaphie (Zypiexa) & Fluoxetine (Prozac)
Retrieved from 05 September 2007.

https://web.archive.org/web/20070905190454/https://erowid.org/experiences/exp.php?ID=44850



"For the past 2 months I have been taking 6 mg Zyprexa and 25 mg Prozac under the name Symbyax daily. I have taken mushrooms before, but never while on Symbyax. **Tonight I ate one gram of powerful mushrooms with no effects after 4 hours.** I did some research and found a report of a person **eating 8 g of cubensis mushrooms while on Zyprexa with no effects**"

6. BIGWOOD (1982) "Variation of psilocybin and psilocin levels with repeated flushes (harvests) of mature sporocarps of Psilocybe cubensis (earle) singer" Journal of Ethnopharmacology. 5(3):287-291.

From page 289

TABLE 1

The dry weight variation of psilocybin and psilocin levels in *Psilocybe cubensis* as a function of flush number (quantified by HPLC)

Flush M No. – (r	Miniculture	Miniculture No. 1		No. 2	Miniculture No. 3	
	Psilocybin (mg/g)	Psilocin (mg/g)	Psilocybin (mg/g)	Psilocin (mg/g)	Psilocybin (mg/g)	Psilocir (mg/g)
1	8.3	0.5	5.1	0	7.6	0
2	6.5	1.5	7.3	0	6.2	0
3	13.3	1.0	4.7	1.7	5.3	0.9
4	4.8	2.6	3.7	2.9	3.2	1.8
5	-	_	5.2	2.2	6.7	1.7
6	6.8	0.5	-		_	_

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL:

https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

	From paragraph 25 "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit."
	7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: <u>https://web.archive.org/web/20200928082744/https://www.psyched</u> <u>elicpassage.com/psychedelic-dosage-guide-how-much-of-each- substance-to-take/</u>
	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: $50 - 150 \mu g$ (micrograms) per individual, $200 + \mu g$ in highly supportive settingsthe most common form of LSD comes on blotter paper , which is an absorbent paper soaked in a solution of LSD. An average sheet of blotter paper has about 100 uniform tabs containing about 100 μg per tab."
	4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: <u>https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109</u>
	From paragraph 5 "Quetiapine has antagonist actions at 5-
	HT2A receptors, one of the key properties of second-generation
	antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
14. The method of	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION
claim 9, wherein the	PRODUCT FOR THE TREATMENT OF NEUROLOGICAL
duration shortening	AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
receptor antagonist.	From claim 1 "A pharmaceutical combination product
	comprising: compound described by the following formula (I):



15. The method of claim 14, wherein the duration shortening agent is chosen from the group consisting of pimavanserin, salts thereof, analogs thereof, and homologs thereof.

1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)

From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):



wherein **R1** is selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl;

wherein **R2** is selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl;

wherein **R3** is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy;

wherein **R5** is selected from the group consisting of **deuterium** (2H) and protium (1H); and

(ii) a 5-HT2A receptor antagonist;

for use as a medicament."

From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula** (I) is selected from the group consisting of N,N**dimethyltryptamine**, **5-methoxy-N,N-dimethyltryptamine**, N,N-

	diethyltryptamine, N,N-dipropyltryptamine and N,N- diisopropyltryptamine."
	From claim 4 "The combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, Pimavanserin , Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK- 215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150."
	From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
16. The method of claim 15, wherein the pimavanserin is administered in an amount of 1-100 mg.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
	From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):
	$\begin{array}{c} R_3 \\ R_4 \\ R_5 \\$
	n-propyl, allyl and isopropyl;

wherein R2 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and
wherein R4 is selected from the group consisting of hydrogen,
wherein R5 is selected from the group consisting of deuterium
(2H) and protium (1H); and
(ii) a 5-HT2A receptor antagonist;
for use as a medicament."
From claim 3 "The combination product for use according to anyone of claims 1 -2 wherein the compound described by formula (I) is selected from the group consisting of N,N- dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N- diethyltryptamine, N,N-dipropyltryptamine and N,N- diisopropyltryptamine."
From claim 4 "The combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, Pimavanserin , Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK- 215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150."
From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
From page 29 "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise 0.5 -1000 mg of a compound described by formula (I) and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist ."

	 8. FDA (2016) "NUPLAZID (PIMAVANSERIN): HIGHLIGHTS OF PRESCRIBING INFORMATION" URL: <u>https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318</u> <u>lbl.pdf</u> From page 1 "DOSAGE AND ADMINISTRATION: Recommended dose is 34 mg, taken orally as two 17 mg tablets once daily, without titration."
17. The method of claim 9, wherein the psychedelic drug and duration shortening agent are in dosage units chosen from the group consisting of separate dosage units, in the same dosage unit with the same release profiles, and in the same dosage unit with different release profiles.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I): $R_{3} \qquad R_{4} \qquad R_{5} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{5} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{5} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{5} \qquad R_{5$
	wherein R1 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
	wherein R2 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
	wherein R3 is selected from the group consisting of hydrogen , methoxy, methyl, hydroxy and a halogen; and
	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;

	wherein R5 is selected from the group consisting of deuterium						
	(2H) and protium (1H); and						
	(ii) a 5-HT2A receptor antagonist;						
	for use as a medicament."						
	From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."						
	From page 15 "The term "combination product' can refer to (i) a product comprised of two or more regulated components that are physically, chemically, or otherwise combined or mixed and produced as a single entity; (ii) two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products; (iii) a drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or (iv) any investigational drug, device, or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect."						
18. The method of claim 9, further including the step of reducing the time of subjective effects	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From claim 1 "A pharmaceutical combination product						
or/and reducing the amount of effects including any drug effect, bad drug effect, anxiety, ego- dissolution, and autonomic response	comprising: compound described by the following formula (I):						
measures by 10-100% compared with a treatment of the same							
amount of the							
-------------------------	--	--	--	--	--	--	--
psychedelic drug alone.							
	Ro D						
	13 13 13 14 5 5 13						
	$\langle \rangle = R = 5$						
	$\rightarrow - \langle D^{\circ} R \rangle$						
	(
	N						
	11						
	H						
	when in D1 is calculated from the group consisting of mothed when						
	n propyl allyl and isopropyl.						
	n-propyr, anyr and isopropyr,						
	wherein B2 is selected from the group consisting of methyl , athyl						
	n-propyl allyl and isopropyl:						
	wherein R3 is selected from the group consisting of hydrogen,						
	methoxy, methyl, hydroxy and a halogen; and						
	wherein R4 is selected from the group consisting of hydrogen.						
	hydroxy, phosphoryloxy and acetoxy;						
	wherein R5 is selected from the group consisting of deuterium						
	(2H) and protium (1H); and						
	(ii) a 5-HT2A receptor antagonist;						
	for use as a medicament."						
	From page 32 "In a preferred embodiment, the 5-HT2A receptor						
	antagonist present in the combination product alleviates and/or						
	eminates the nanucinogenic and/or psychedelic side effects						
	caused by a compound described by formula (1)."						
19. The method of	1 Int'l Pat Dec No $WO/2010/081764$ "COMPINATION						
claim 9 further	PRODUCT FOR THE TREATMENT OF NEUROL OCICAL						
providing no recurrence	AND/OR DEVCHIATRIC DISOPDEDS" (Dublished 02 May 2010)						
of the psychodelic drug	AND/OK I S I CHIA I KIC DISOKDEKS (I ubilsiicu 02 May 2019)						
effects after the	From claim 1 "A pharmaceutical combination product						
	comprising: compound described by the following formule (I):						
	comprising, compound described by the following formula (1).						

	-						
duration shortening							
agent is administered.							
	1 1 1 1 1 1 1 1 1						
	P^{-} P^{2} R^{-}						
	$(') $ R_2						
	N ²						
	L						
	П						
	wherein R1 is selected from the group consisting of methyl ethyl						
	n-propyl, allyl and isopropyl:						
	wherein R2 is selected from the group consisting of methyl ethyl						
n-propyl, allyl and isopropyl;							
	r r , , , , , , , , , , , , , , , , , ,						
	wherein R3 is selected from the group consisting of hydrogen,						
	methoxy, methyl, hydroxy and a halogen; and						
	wherein R4 is selected from the group consisting of hydrogen,						
	hydroxy, phosphoryloxy and acetoxy;						
	wherein R5 is selected from the group consisting of deuterium						
	(2H) and protium (1H); and						
	(ii) a 5-H12A receptor antagonist;						
	C						
	for use as a medicament.						
	Erom page 22 "In a proformed embediment the 5 UT2A recentor						
	antagonist present in the combination product alloviates and/or						
	allagonist present in the combination product aneviates and/or eliminates the hallucinogenic and/or neverhedelic side affects						
	caused by a compound described by formula (T) "						
	caused by a compound described by formula (1).						
20. The method of	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION						
claim 9, further	PRODUCT FOR THE TREATMENT OF NEUROLOGICAL						
including a step chosen	AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)						
from the group							
consisting of reducing	From claim 1 "A pharmaceutical combination product						
time and/or degree of	comprising: compound described by the following formula (I):						

cognitive impairment due to the psychedelic drug, reducing time of treatment session supervision by medical personnel, reducing intensity and/or duration of anxiety or any other acute adverse effects in response to the psychedelic drug, reducing expected acute adverse effects intensity and/or duration due to inadvertent administration of a high dose of the psychedelic drug, reducing expected acute adverse effects intensity and/or duration due to intentional intake of the psychedelic drug, and reducing expected acute adverse effects duration and/or intensity due to intentional intake of the psychedelic drug in doses considered too high or producing too strong effects after administration.



wherein **R1** is selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl;

wherein **R2** is selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl;

wherein **R3** is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

wherein **R4** is selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy;

wherein **R5** is selected from the group consisting of **deuterium** (2H) and protium (1H); and

(ii) a 5-HT2A receptor antagonist;

for use as a medicament."

From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."

From page 14 "The terms "hallucinogenic side effects" and "psychedelic side effects" are used in the present application interchangeably to refer to unwanted and/or unintended secondary effects caused by the administration of a medicament to an individual resulting in subjective experiences being qualitatively different from those of ordinary consciousness. These experiences can include derealization, depersonalization,

	hallucinations and/or sensory distortions in the visual, auditory, olfactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or any other substantial subjective changes in cognition, memory, emotion and consciousness. "
21. A method of stopping the acute duration of action of a psychedelic drug in an individual, including the steps of: administering a duration shortening and/or effect reducing agent to the individual after the individual has taken a psychedelic drug; and stopping the acute effects of the psychedelic drug.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I): $R_{3} \qquad R_{4} \qquad R_{5} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{5} \qquad R_{5$
	wherein R1 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
	wherein R2 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
	wherein R3 is selected from the group consisting of hydrogen , methoxy, methyl, hydroxy and a halogen; and
	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;
	wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and
	(ii) a 5-HT2A receptor antagonist;
	for use as a medicament."

From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."

From page 32 "A compound described by formula (I) and a 5-HT2A receptor antagonist may be administered together or separately to an individual who suffers from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders.

From **page 32** "In a preferred embodiment, a compound described by formula (I) may be administered to an individual who is already being administered a 5-HT2A receptor antagonist and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. Conversely, in an alternative embodiment, a 5-HT2A receptor antagonist may be administered to an individual who is already being administered a compound described by formula (I) and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders."

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: <u>https://web.archive.org/web/20131015121257/https://erowid.org/ex</u>periences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit."

7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL:

	https://web.archive.org/web/20200928082744/https://www.psyched elicpassage.com/psychedelic-dosage-guide-how-much-of-each- substance-to-take/ "Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 μg (micrograms) per individual, 200+ μg in highly supportive settingsthe most common form of LSD comes on blotter paper , which is an absorbent paper soaked in a solution of LSD. An average sheet of blotter paper has about 100 uniform tabs containing about 100 μg per tab ."
	 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism- of-action-of-quetiapine-2109 From paragraph 5 "Quetiapine has antagonist actions at 5- HT2A receptors, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
22. The method of claim 21, wherein the individual is experiencing an adverse effect due to the psychedelic drug.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):
	$\begin{array}{c} R_{3} \\ R_{4} \\ R_{5} \\$

wherein R2 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
wherein R3 is selected from the group consisting of hydrogen , methoxy, methyl, hydroxy and a halogen; and
wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;
wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and
(ii) a 5-HT2A receptor antagonist;
for use as a medicament."
From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
From page 32 "A compound described by formula (I) and a 5- HT2A receptor antagonist may be administered together or separately to an individual who suffers from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders.
From page 32 "In a preferred embodiment, a compound described by formula (I) may be administered to an individual who is already being administered a 5-HT2A receptor antagonist and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. Conversely, in an alternative embodiment, a 5-HT2A receptor antagonist may be administered to an individual who is already being administered a compound described by formula (I) and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders."
From page 14 "The terms "hallucinogenic side effects" and "psychedelic side effects" are used in the present application interchangeably to refer to unwanted and/or unintended secondary effects caused by the administration of a medicament to an individual resulting in subjective experiences being qualitatively different from those of ordinary consciousness.

These experiences can include derealization, depersonalization, hallucinations and/or sensory distortions in the visual, auditory, olfactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or **any other substantial subjective changes in cognition, memory, emotion and consciousness.**"

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, **I would recommend it to anyone, at least to have as part of a psychedelic crisis kit**."

7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: <u>https://web.archive.org/web/20200928082744/https://www.psyched</u> <u>elicpassage.com/psychedelic-dosage-guide-how-much-of-each-</u> <u>substance-to-take/</u>

"Lysergic Acid Diethylamide (LSD): Recommended Dosage: $50 - 150 \mu g$ (micrograms) per individual, $200 + \mu g$ in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 \mu g per tab."**

4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: <u>https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109</u>

From paragraph 5 "Quetiapine has antagonist actions at 5-HT2A receptors, one of the key properties of second-generation

	antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
23. The method of claim 21, wherein the individual has overdosed on the psychedelic drug.	 Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):
	R_{3} R_{4} R_{5} R_{7} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2}
	wherein R1 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
	wherein R2 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
	wherein R3 is selected from the group consisting of hydrogen , methoxy, methyl, hydroxy and a halogen; and
	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;
	wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and
	(ii) a 5-HT2A receptor antagonist;
	for use as a medicament."
	From claim 4 "The combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is selected from the group consisting of Methiothepin, Ritanserin,

Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150."

From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."

From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5** -1000 mg of a compound described by formula (I) and/or **0.5** - 1000 mg of a **5-HT2A receptor antagonist**."

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit."

7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psyched elicpassage.com/psychedelic-dosage-guide-how-much-of-eachsubstance-to-take/

	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 –
	150 μ g (micrograms) per individual, 200+ μ g in highly supportive
	settingsthe most common form of LSD comes on blotter paper,
	which is an absorbent paper soaked in a solution of LSD. An
	average sheet of blotter paper has about 100 uniform tabs
	containing about 100 µg per tab."
	4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: <u>https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109</u>
	From paragraph 5 "Ouetiapine has antagonist actions at 5-
	HT2A receptors , one of the key properties of second-generation
	antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine
	has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
24. The method of	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION
claim 21, wherein the	PRODUCT FOR THE TREATMENT OF NEUROLOGICAL
duration shortening	AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
agent is administered 1	
minute to 24 hours after	From claim 1 "A pharmaceutical combination product
administering the	comprising: compound described by the following formula (1):
psychedelic drug.	
	$R_3 \qquad R_4 \qquad R_5 \qquad R_7 \qquad R_1 \qquad R_2 \qquad R_2 $
	wherein P1 is selected from the group consisting of methyl, othyl
	n-propyl, allyl and isopropyl;
	wherein R2 is selected from the group consisting of methyl ethyl
	n-propyl, allyl and isopropyl:
	wherein R3 is selected from the group consisting of hvdrogen.
	methoxy, methyl, hydroxy and a halogen; and

wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;
wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and
(ii) a 5-HT2A receptor antagonist;
for use as a medicament."
From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
From page 32 "A compound described by formula (I) and a 5- HT2A receptor antagonist may be administered together or separately to an individual who suffers from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders.
From page 32 "In a preferred embodiment, a compound described by formula (I) may be administered to an individual who is already being administered a 5-HT2A receptor antagonist and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. Conversely, in an alternative embodiment, a 5-HT2A receptor antagonist may be administered to an individual who is already being administered a compound described by formula (I) and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders."
3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

	_							
	DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)			
	T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)			
	T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)			
	T+ 4:00	200 mg	oral	Pharms - Ibuprofen				
	T+ 6:30	1 glass	oral	Alcohol - Beer/Wine				
	From paragraph 25 "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit."							
	7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psyched elicpassage.com/psychedelic-dosage-guide-how-much-of-each- substance-to-take/							
	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: $50 - 150 \mu g$ (micrograms) per individual, $200 + \mu g$ in highly supportive settingsthe most common form of LSD comes on blotter paper , which is an absorbent paper soaked in a solution of LSD. An average sheet of blotter paper has about 100 uniform tabs containing about 100 μg per tab."							
	4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism- of-action-of-quetiapine-2109							
	From paragraph 5 "Quotianing has antegonist actions at 5							
	HT2A receptors , one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapin has higher affinity for 5-HT2A receptors than for D2 receptors [3].							
25. The method of claim 21, wherein the psychedelic drug is a 5HT2A agonist chosen	1. Int'l Pat. Doo PRODUCT FO AND/OR PSYC	2. No. WO/201 R THE TREA CHIATRIC DIS	9/08 TME SOR	1764 "COMBINA NT OF NEUROL DERS" (Published	TION OGICAL 02 May 2019)			
from the group	From claim 1 "	A pharmaceu	tical	combination pro	duct			
consisting of LSD,	comprising: co	mpound desc	ribed	1 by the following	iormula (1):			
mescaline, 5-methoxy-								
N,N-								
dimethyltryptamine (5- MeO-DMT),								

dimethyltryptamine (DMT), 2,5-dimethoxy-4-iodoamphetamine (DOI), 2,5-dimethoxy-4-bromoamphetamie (DOB), salts thereof, tartrates thereof, solvates thereof, solvates thereof, deuterated forms thereof, analogs thereof, and homologues thereof.



wherein **R1** is selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl;

wherein **R2** is selected from the group consisting of **methyl**, ethyl, n-propyl, allyl and isopropyl;

wherein **R3** is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

wherein **R4 is** selected from the group consisting of hydrogen, hydroxy, **phosphoryloxy** and acetoxy;

wherein **R5** is selected from the group consisting of **deuterium** (2H) and protium (1H); and

(ii) a 5-HT2A receptor antagonist;

for use as a medicament."

From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."

From page 32 "A compound described by formula (I) and a 5-HT2A receptor antagonist may be administered together or separately to an individual who suffers from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. From **page 32** "In a preferred embodiment, a compound described by formula (I) may be administered to an individual who is already being administered a 5-HT2A receptor antagonist and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. Conversely, in an alternative embodiment, a 5-HT2A receptor antagonist may be administered to an individual who is already being administered a compound described by formula (I) and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders."

From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula** (I) is selected from the group consisting of N,N**dimethyltryptamine**, **5**-methoxy-N,N-**dimethyltryptamine**, N,N**diethyltryptamine**, N,N-**dipropyltryptamine** and N,N**diisopropyltryptamine**."

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: <u>https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844</u>

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit."

7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: <u>https://web.archive.org/web/20200928082744/https://www.psyched</u> <u>elicpassage.com/psychedelic-dosage-guide-how-much-of-each-</u> <u>substance-to-take/</u>

	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: $50 - 150 \mu g$ (micrograms) per individual, $200 + \mu g$ in highly supportive settingsthe most common form of LSD comes on blotter paper , which is an absorbent paper soaked in a solution of LSD. An average sheet of blotter paper has about 100 uniform tabs containing about 100 μg per tab."
	4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism- of-action-of-quetiapine-2109
	From paragraph 5 " Quetiapine has antagonist actions at 5- HT2A receptors , one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
26. The method of claim 21, wherein the psychedelic drug is administered in an amount that provides an effect for at least 2 hours.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):
	R_{3} R_{4} R_{5} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2}
	wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;
	wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;
	wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;
wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and
(ii) a 5-HT2A receptor antagonist;
for use as a medicament."
From claim 3 "The combination product for use according to anyone of claims 1 -2 wherein the compound described by formula (I) is selected from the group consisting of N,N- dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N- diethyltryptamine, N,N-dipropyltryptamine and N,N- diisopropyltryptamine."
From page 29 "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise 0.5 -1000 mg of a compound described by formula (I) and/or 0.5 - 1000 mg of a 5- HT2A receptor antagonist."
2. VALERIANI (2015) "Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms" Human Psychopharmacology: Clinical and Experimental. 30:249-254.
From page 250 "In most cases, users reported here to ingest olanzapine at relatively small dosages, usually ranging from 5 to 10 mg once a day for just a few days as a "terminator"/"modulator" of unwanted NPS psychedelic effects."
From page 251 "Most online reports about olanzapine were here related to its use as a short-term, self-prescribed treatment for the psychedelic crises/"bad trips." Symptoms of psychedelic crises usually last a few hours, depending on the drug taken and dose ingested (Mangot, 2013). Indeed, SC's effects may last 1–4 h (Hoyte et al., 2012); tryptamines' effects 2–6 h (Hallock et al., 2013); lysergic acid diethylamide [LSD] 6–14 h (Krebs and Johansen, 2013); and mescaline 8–16 h (Trachsel, 2012)."

From page 251 "There are already published data showing the effectiveness of olanzapine and, in general, of second-generation antipsychotics (SGA), as first-line treatments in psychotic disorders induced by drugs such as cannabis (Bersani et al., 2002a, 2002b; Sevy et al., 2011) and cocaine (Testa et al., 2013). Compared with first-generation antipsychotics (FGA), SGA may present with some advantages while treating drug-induced psychosis, including the following: (i) SGA induce fewer/no extrapyramidal symptoms (Ohno et al., 2013); (ii) SGA quickly dissociate from D2 receptors, unlike FGA/haloperidol, and hence may seem to be less associated with dysphoria and interference with drug reward anticipation/craving (Juckel et al., 2006); (iii) SGA seem more effective in the treatment of negative symptoms (Buchanan et al., 2005), alter positively mood (McIntyre et al., 2004), and have a positive impact on cognition (Bersani et al., 2011); and (iv) SGA act as antagonists of 5HT2A receptor, which is the main target of most hallucinogenic drugs (Potvin et al., 2003). From this point of view, both clozapine and olanzapine may present with a distinct advantage in reducing drug-induced psychotic symptoms (Murthy and Chand, 2012)."

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit."

7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psyched elicpassage.com/psychedelic-dosage-guide-how-much-of-eachsubstance-to-take/

	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: $50 - 150 \mu g$ (micrograms) per individual, $200 + \mu g$ in highly supportive settingsthe most common form of LSD comes on blotter paper , which is an absorbent paper soaked in a solution of LSD. An average sheet of blotter paper has about 100 uniform tabs containing about 100 μg per tab."
	4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: <u>https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109</u>
	From paragraph 5 " Quetiapine has antagonist actions at 5- HT2A receptors , one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
27. The method of claim 25, wherein the psychedelic drug is administered in an amount chosen from the group consisting of 0.01-1 mg LSD, 10-50 mg psilocybin, 100-800 mg mescaline, 20-100 mg DMT, 0.1-5 mg DOI, and 0.1-5 mg DOB.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I): $R_{3} \qquad R_{4} \qquad S_{6} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{2} \qquad R_{3} \qquad R_{4} \qquad R_{5} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{2} \qquad R_{3} \qquad R_{4} \qquad R_{5} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{3} \qquad R_{4} \qquad R_{5} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{3} \qquad R_{4} \qquad R_{5} \qquad R_{5} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{3} \qquad R_{4} \qquad R_{5} \qquad R_{5} \qquad R_{5} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{3} \qquad R_{4} \qquad R_{5} \qquad R_{5$
	wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

wherein R3 is selected from the group consisting of hydrogen
mathewy methyl hydroyy and a halogon, and
memoxy, memyi, nyuroxy anu a naiogen, anu
wherein R4 is selected from the group consisting of hydrogen,
hydroxy, phosphoryloxy and acetoxy;
wherein $R5$ is selected from the group consisting of deuterium (2H)
and protium (11), and
and produin (1H); and
(ii) a 5-H12A receptor antagonist;
for use as a medicament."
From claim 3 "The combination product for use according to
anyone of claims 1, 2 wherein the compound described by formula
anyone of claims $1-2$ wherein the compound described by formula (\mathbf{T}) is called a from the energy equal time of \mathbf{N} \mathbf{N}
(1) is selected from the group consisting of N,N-
dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-
diethyltryptamine, N,N-dipropyltryptamine and N,N-
diisopropyltryptamine."
From nage 29 "In a preferred embodiment, the combination product
is administered at least two times, preferably more than two times
is administered at least two times, preferably more than two times.
A dosage of the combination product can comprise 0.5 -1000 mg of
a compound described by formula (I) and/or 0.5 - 1000 mg of a 5-
HT2A receptor antagonist."
2 VALERIANI (2015) "Olanzanine as the ideal "trin terminator"?
2. VALERIARY (2013) Oranzaphic as the rotar trip terminator :
Analysis of online reports relating to antipsycholics use and misuse
following occurrence of novel psychoactive substance-related
psychotic symptoms" Human Psychopharmacology: Clinical and
Experimental. 30:249-254.
-
From page 250 "In most cases, users reported here to ingest
olanzanine at relatively small dosages usually ranging from 5 to
10 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
to mg once a day for just a few days as a
"terminator"/"modulator" of unwanted NPS psychedelic
effects."
From page 251 "Most online reports about olanzapine were here
related to its use as a short-term self-prescribed treatment for the
neurohadalia arigag/"had tring " Summtoma of neurohadalia arigag
psychedene enses/ bad unps. Symptoms of psychedene erises
usually last a few hours, depending on the drug taken and dose
ingested (Mangot, 2013). Indeed, SC's effects may last 1–4 h
(Hoyte et al., 2012); tryptamines' effects 2–6 h (Hallock et al.,
2013); lysergic acid diethylamide [LSD] 6–14 h (Krebs and
Johansen 2013), and mescaline 8-16 h (Trachsol 2012) "
oonanisen, 2013), and mescanne 0–10 n (11 achsel, 2012).

From page 251 "There are already published data showing the effectiveness of olanzapine and, in general, of second-generation antipsychotics (SGA), as first-line treatments in psychotic disorders induced by drugs such as cannabis (Bersani et al., 2002a, 2002b; Sevy et al., 2011) and cocaine (Testa et al., 2013). Compared with first-generation antipsychotics (FGA), SGA may present with some advantages while treating drug-induced psychosis, including the following: (i) SGA induce fewer/no extrapyramidal symptoms (Ohno et al., 2013); (ii) SGA quickly dissociate from D2 receptors, unlike FGA/haloperidol, and hence may seem to be less associated with dysphoria and interference with drug reward anticipation/craving (Juckel et al., 2006); (iii) SGA seem more effective in the treatment of negative symptoms (Buchanan et al., 2005), alter positively mood (McIntyre et al., 2004), and have a positive impact on cognition (Bersani et al., 2011); and (iv) SGA act as antagonists of 5HT2A receptor, which is the main target of most hallucinogenic drugs (Potvin et al., 2003). From this point of view, both clozapine and olanzapine may present with a distinct advantage in reducing drug-induced psychotic symptoms (Murthy and Chand, 2012)."

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit."

7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: https://web.archive.org/web/20200928082744/https://www.psyched elicpassage.com/psychedelic-dosage-guide-how-much-of-eachsubstance-to-take/

	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 –
	150 μ g (micrograms) per individual, 200+ μ g in highly supportive
	settingsthe most common form of LSD comes on blotter paper,
	which is an absorbent paper soaked in a solution of LSD. An
	average sheet of blotter paper has about 100 uniform tabs
	containing about 100 µg per tab."
	4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism- of-action-of-quetiapine-2109
	From paragraph 5 "Quetiapine has antagonist actions at 5- HT2A receptors, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
28. The method of	1 Int'l Pat Doc No. WO/2019/081764 "COMBINATION
claim 21 wherein the	PRODUCT FOR THE TREATMENT OF NEUROLOGICAL
duration shortening	AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
agent is a 5HT2A	
receptor antagonist	From claim 1 "A pharmaceutical combination product
receptor untugonist.	comprising: compound described by the following formula (I) ⁻
	$R_3 \qquad R_4 \qquad R_5 \qquad R_5 \qquad R_1 \\ R_1 \qquad R_2 \qquad R_2 \qquad R_2 \qquad R_1 \qquad R_2 \qquad R_2 \qquad R_1 \qquad R_2 $
	wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;
	wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;
	wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

	 wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy; wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and (ii) a 5-HT2A receptor antagonist; for use as a medicament." From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
29. The method of claim 28, wherein the duration shortening agent is chosen from the group consisting of pimavanserin, salts thereof, analogs thereof, and homologs thereof.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I): $R_{3} \qquad R_{4} \qquad R_{5} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{5} \qquad R_{5$
	 wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;
	wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and
	(ii) a 5-HT2A receptor antagonist;
	for use as a medicament."
	From claim 3 "The combination product for use according to anyone of claims 1 -2 wherein the compound described by formula (I) is selected from the group consisting of N,N- dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N- diethyltryptamine, N,N-dipropyltryptamine and N,N- diisopropyltryptamine."
	From claim 4 "The combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, Pimavanserin , Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK- 215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150."
	From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
30. The method of	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION
claim 29, wherein the	PRODUCT FOR THE TREATMENT OF NEUROLOGICAL
pimavanserin is	AND/OK PSYCHIATKIC DISOKDERS" (Published 02 May 2019)
amount of 1-100 mg.	From claim 1 "A pharmaceutical combination product
	comprising: compound described by the following formula (I):



	Agomelatine, Pimavanserin , Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK- 215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150." From page 29 "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise 0.5 -1000 mg of a compound described by formula (I) and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist ."
	8. FDA (2016) "NUPLAZID (PIMAVANSERIN): HIGHLIGHTS OF PRESCRIBING INFORMATION" URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318 lbl.pdf From page 1 "DOSAGE AND ADMINISTRATION: Recommended dose is 34 mg, taken orally as two 17 mg tablets once daily, without titration."
31. The method of claim 21, further providing no recurrence of the psychedelic drug effects after the duration shortening agent is administered.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):
	R_{3} R_{4} R_{5} R_{7} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2}

	1
	wherein R1 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
	wherein R2 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
	wherein R3 is selected from the group consisting of hydrogen , methoxy, methyl, hydroxy and a halogen; and
	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;
	wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and
	(ii) a 5-HT2A receptor antagonist;
	for use as a medicament."
	From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
32. A method of stopping psychosis due to psychedelic administration	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
including the steps of: administering a duration shortening	From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):
agent to the individual after the individual has taken a psychedelic drug; and stopping psychosis caused by the psychedelic drug.	$\begin{array}{c} R_{3} \\ R_{4} \\ R_{5} \\ R_{7} \\ R_{2} \\ R_{7} \\ R_{2} \\ R_{7} \\ R_{2} \\ R_{7} \\ R_{2} \\ R_{7} \\ R_{1} \\ R_{2} \\ R_{2} \\ R_{2} \\ R_{1} \\ R_{2} \\ R_{2} \\ R_{1} \\ R_{2} \\$
	R ⁵
	H

wherein R1 is selected from the group consisting of methyl , ethyl,
n-propyl, allyl and isopropyl;
wherein R2 is selected from the group consisting of methyl , ethyl,
n-propyl, allyl and isopropyl;
wherein R3 is selected from the group consisting of hydrogen,
methoxy, methyl, hydroxy and a halogen; and
wherein R4 is selected from the group consisting of hydrogen,
hydroxy, phosphoryloxy and acetoxy;
wherein R5 is selected from the group consisting of deuterium
(2H) and protium (1H): and
(ii) a 5-HT2A recentor antagonist
(n) a 5 m 2m receptor anagomst,
for use as a medicament "
From page 32 "In a proferred ambediment the 5 HT?A recentor
antagonist present in the combination product allowistes and/or
antagonist present in the combination product aneviates and/or
eliminates the hallucinogenic and/or psychedelic side effects
caused by a compound described by formula (1)."
From page 14 "The terms "hallucinogenic side effects" and
"psychedelic side effects" are used in the present application
interchangeably to refer to unwanted and/or unintended
secondary effects caused by the administration of a medicament to
an individual resulting in subjective experiences being
qualitatively different from those of ordinary consciousness.
These experiences can include derealization, depersonalization,
hallucinations and/or sensory distortions in the visual, auditory,
olfactory, tactile, proprioceptive and/or interoceptive spheres and/or
any other perceptual modifications, and/or any other substantial
subjective changes in cognition, memory, emotion and
consciousness."
9 NIMH (2021) "Understanding Psychosis" Retrieved 13 May
2021 URL:
https://web.archive.org/web/20210503133654/https://www.nimb.nih
gov/health/publications/understanding_psychosis/
.gov/nearth/publications/understanding-psychosis/
"The word psychosis is used to describe conditions that effect the
mind whom there has been some loss of contact with us 1 ² tr."
mind, where there has been some loss of contact with reality."

"Symptoms of psychosis include delusions (false beliefs) and hallucinations (seeing or hearing things that others do not see or hear). Other symptoms include incoherent or nonsense speech and behavior that is inappropriate for the situation. A person in a psychotic episode also may experience depression, anxiety, sleep problems, social withdrawal, lack of motivation, and difficulty functioning overall."

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 12** "Visualizations began at around 10:30 with crawling carpeting and changes in color hues. I felt as if my head was being detached from the rest of my body. Looking outside I noticed the color of the tree outside our home was leaning closer and closer to the window."

From **paragraph 12** "By around 10:45 - 11:00, the peak is in full swing and I am melting into the floor, **getting very intense**, **hard to see**, **my visual field is sideways and standing up straight becomes hard**. Wow, this is really good acid. **Maybe too good**, **I thought**, **this is only the beginning**, **time to cut this short**."

From **paragraph 13** "At 11:30 (or thereabouts) I consumed approx. 66mg of the Quetiapine."

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit **cutting the LSD short**) from the psychedelic aspect of my trip using the Seroquel, **I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.**"

7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: <u>https://web.archive.org/web/20200928082744/https://www.psyched</u> <u>elicpassage.com/psychedelic-dosage-guide-how-much-of-eachsubstance-to-take/</u>

	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: $50 - 150 \mu g$ (micrograms) per individual, $200 + \mu g$ in highly supportive settingsthe most common form of LSD comes on blotter paper , which is an absorbent paper soaked in a solution of LSD. An average sheet of blotter paper has about 100 uniform tabs containing about 100 μg per tab."		
	4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: <u>https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109</u>		
	From paragraph 5 " Quetiapine has antagonist actions at 5- HT2A receptors , one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."		
33. The method of claim 32, wherein said stopping step further includes stopping or reducing a symptom chosen from the group consisting of delusions, hallucinations, talking incoherently, and agitation.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I): $R_{3} \qquad R_{4} \qquad R_{5} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{5} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{5} \qquad R_{5$		
	 wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl; 		

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL:

https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 12** "Visualizations began at around 10:30 with crawling carpeting and changes in color hues. I felt as if my head was being detached from the rest of my body. Looking outside I noticed the color of the tree outside our home was leaning closer and closer to the window."

From **paragraph 12** "By around 10:45 - 11:00, the peak is in full swing and I am melting into the floor, **getting very intense**, **hard to see**, **my visual field is sideways and standing up straight becomes hard**. Wow, this is really good acid. **Maybe too good**, **I thought**, **this is only the beginning**, **time to cut this short**."

From **paragraph 13** "At 11:30 (or thereabouts) I consumed approx. 66mg of the Quetiapine."

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit **cutting the LSD short**) from the psychedelic aspect of my trip using the Seroquel, **I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.**"

7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: <u>https://web.archive.org/web/20200928082744/https://www.psyched</u> <u>elicpassage.com/psychedelic-dosage-guide-how-much-of-each-</u> <u>substance-to-take/</u>

"Lysergic Acid Diethylamide (LSD): Recommended Dosage: $50 - 150 \mu g$ (micrograms) per individual, $200 + \mu g$ in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. An average sheet of blotter paper has about 100 uniform tabs containing about 100 μg per tab."

	 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanism- of-action-of-quetiapine-2109 From paragraph 5 "Quetiapine has antagonist actions at 5- HT2A receptors, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
34. The method of claim 32, wherein the duration shortening agent is administered 1	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
minute to 24 hours after administering the psychedelic drug.	From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):
	$ \begin{array}{c} R_{3} \\ R_{4} \\ R_{5} \\ R_{$
	wherein R1 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
	wherein R2 is selected from the group consisting of methyl , ethyl, n-propyl, allyl and isopropyl;
	wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and
	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;
	wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and

(ii) a 5-HT2A receptor antagonist;
for use as a medicament."
From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
From page 32 "A compound described by formula (I) and a 5- HT2A receptor antagonist may be administered together or separately to an individual who suffers from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders.
From page 32 "In a preferred embodiment, a compound described by formula (I) may be administered to an individual who is already being administered a 5-HT2A receptor antagonist and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. Conversely, in an alternative embodiment, a 5-HT2A receptor antagonist may be administered to an individual who is already being administered a compound described by formula (I) and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders."
From page 14 "The terms "hallucinogenic side effects" and "psychedelic side effects" are used in the present application interchangeably to refer to unwanted and/or unintended secondary effects caused by the administration of a medicament to an individual resulting in subjective experiences being qualitatively different from those of ordinary consciousness. These experiences can include derealization, depersonalization, hallucinations and/or sensory distortions in the visual, auditory, olfactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or any other substantial subjective changes in cognition, memory, emotion and consciousness."
9. NIMH (2021) "Understanding Psychosis" Retrieved 13 May 2021. URL:

https://web.archive.org/web/20210503133654/https://www.nimh.nih .gov/health/publications/understanding-psychosis/

"The word psychosis is used to describe conditions that affect the mind, where there has been some loss of contact with reality."

"Symptoms of psychosis include delusions (false beliefs) and hallucinations (seeing or hearing things that others do not see or hear). Other symptoms include incoherent or nonsense speech and behavior that is inappropriate for the situation. A person in a psychotic episode also may experience depression, anxiety, sleep problems, social withdrawal, lack of motivation, and difficulty functioning overall."

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL:

https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 12** "Visualizations began at around 10:30 with crawling carpeting and changes in color hues. I felt as if my head was being detached from the rest of my body. Looking outside I noticed the color of the tree outside our home was leaning closer and closer to the window."

From **paragraph 12** "By around 10:45 - 11:00, the peak is in full swing and I am melting into the floor, **getting very intense**, **hard to see**, **my visual field is sideways and standing up straight becomes hard**. Wow, this is really good acid. **Maybe too good**, I **thought**, **this is only the beginning**, **time to cut this short**."

From **paragraph 13** "At 11:30 (or thereabouts) I consumed approx. 66mg of the Quetiapine."

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit **cutting the LSD short**) from the psychedelic aspect of my trip using the Seroquel, **I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.**"

	 7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: <u>https://web.archive.org/web/20200928082744/https://www.psyched</u>elicpassage.com/psychedelic-dosage-guide-how-much-of-each-substance-to-take/ "Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 – 150 μg (micrograms) per individual, 200+ μg in highly supportive settingsthe most common form of LSD comes on blotter paper, which is an absorbent paper soaked in a solution of LSD. An average sheet of blotter paper has about 100 uniform tabs
	 containing about 100 μg per tab." 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: <u>https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109</u>
	From paragraph 5 " Quetiapine has antagonist actions at 5- HT2A receptors , one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
35. The method of claim 32, wherein the psychedelic drug is a 5HT2A agonist chosen from the group consisting of LSD, psilocybin, psilocin, mescaline, 5-methoxy-	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):
N,N- dimethyltryptamine (5- MeO-DMT), dimethyltryptamine (DMT), 2,5-dimethoxy- 4-iodoamphetamine (DOI), 2,5-dimethoxy- 4-bromoamphetamie (DOB), salts thereof, tartrates thereof, solvates thereof	$\begin{array}{c} R_{3} \\ R_{4} \\ R_{5} \\$
isomers thereof, deuterated forms thereof, analogs	N ² H
thereof, and	wherein R1 is selected from the group consisting of methyl , ethyl,
---------------------	---
homologues thereof.	n-propyl, allyl and isopropyl;
e	
	wherein R2 is selected from the group consisting of methyl ethyl
	n-propyl allyl and isopropyl:
	n-propyr, anyr and isopropyr,
	wherein P3 is selected from the group consisting of hydrogen
	methows, methyl, hydrowy and a halogany and
	methoxy, methyl, hydroxy and a halogen, and
	wherein K4 is selected from the group consisting of hydrogen,
	hydroxy, phosphoryloxy and acetoxy;
	wherein R5 is selected from the group consisting of deuterium
	(2H) and protium (1H); and
	(ii) a 5-HT2A receptor antagonist;
	for use as a medicament."
	From claim 3 "The combination product for use according to
	anyone of claims 1 -2 wherein the compound described by formula
	(I) is selected from the group consisting of N,N-
	dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N-
	diethyltryptamine. N.N-dipropyltryptamine and N.N-
	diisopropyltryptamine."
	From page 32 "In a preferred embodiment, the 5-HT2A receptor
	antagonist present in the combination product alleviates and/or
	eliminates the hallucinogenic and/or nsychedelic side effects
	caused by a compound described by formula (I) "
	caused by a compound described by formula (1).
	From page 32 "A compound described by formula (I) and a 5-
	HT2A recentor entergonist may be administered together or
	anometaly to an individual who suffers from one or more
	separately to an individual who suffers from one of more
	psychiatric and/or neurological disorders and/or who is at risk of
	suffering from one or more psychiatric and/or neurological
	disorders.
	From page 32 "In a preferred embodiment, a compound described
	by formula (I) may be administered to an individual who is already
	being administered a 5-HT2A receptor antagonist and who is
	suffering from one or more psychiatric and/or neurological disorders
	and/or who is at risk of suffering from one or more psychiatric
	and/or neurological disorders. Conversely, in an alternative
	embodiment, a 5-HT2A receptor antagonist may be administered
	to an individual who is already being administered a compound
	described by formula (I) and who is suffering from one or more

psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders."

From page 14 "The terms "hallucinogenic side effects" and "psychedelic side effects" are used in the present application interchangeably to refer to unwanted and/or unintended secondary effects caused by the administration of a medicament to an individual resulting in subjective experiences being qualitatively different from those of ordinary consciousness. These experiences can include derealization, depersonalization, hallucinations and/or sensory distortions in the visual, auditory, olfactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or any other substantial subjective changes in cognition, memory, emotion and consciousness."

9. NIMH (2021) "Understanding Psychosis" Retrieved 13 May 2021. URL:

https://web.archive.org/web/20210503133654/https://www.nimh.nih .gov/health/publications/understanding-psychosis/

"The word psychosis is used to describe conditions that affect the mind, where there has been some loss of contact with reality."

"Symptoms of psychosis include delusions (false beliefs) and hallucinations (seeing or hearing things that others do not see or hear). Other symptoms include incoherent or nonsense speech and behavior that is inappropriate for the situation. A person in a psychotic episode also may experience depression, anxiety, sleep problems, social withdrawal, lack of motivation, and difficulty functioning overall."

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL:

https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

	From paragraph 12 "Visualizations began at around 10:30 with crawling carpeting and changes in color hues. I felt as if my head was being detached from the rest of my body. Looking outside I noticed the color of the tree outside our home was leaning closer and closer to the window." From paragraph 12 "By around 10:45 - 11:00, the peak is in full
	swing and I am melting into the floor, getting very intense, hard to see, my visual field is sideways and standing up straight becomes hard. Wow, this is really good acid. Maybe too good, I thought, this is only the beginning, time to cut this short."
	From paragraph 13 "At 11:30 (or thereabouts) I consumed approx. 66mg of the Quetiapine."
	From paragraph 25 "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit. "
	7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: <u>https://web.archive.org/web/20200928082744/https://www.psyched</u> <u>elicpassage.com/psychedelic-dosage-guide-how-much-of-each-</u> <u>substance-to-take/</u>
	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: $50 - 150 \mu g$ (micrograms) per individual, $200 + \mu g$ in highly supportive settingsthe most common form of LSD comes on blotter paper , which is an absorbent paper soaked in a solution of LSD. An average sheet of blotter paper has about 100 uniform tabs containing about 100 μg per tab."
	4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: <u>https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109</u>
	From paragraph 5 " Quetiapine has antagonist actions at 5- HT2A receptors , one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
36. The method of claim 32, wherein the psychedelic drug is	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)

administered in an amount that provides an effect for at least 2 hours.

From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):



wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;

wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and**

(ii) a 5-HT2A receptor antagonist;

for use as a medicament."

From claim 3 "The combination product for use according to anyone of claims 1 -2 wherein the compound described by formula (I) is selected from the group consisting of N,Ndimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,Ndiethyltryptamine, N,N-dipropyltryptamine and N,Ndiisopropyltryptamine."

From claim 4 "The combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150."

From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."

From page 14 "The terms "hallucinogenic side effects" and "psychedelic side effects" are used in the present application interchangeably to refer to unwanted and/or unintended secondary effects caused by the administration of a medicament to an individual resulting in subjective experiences being qualitatively different from those of ordinary consciousness. These experiences can include derealization, depersonalization, hallucinations and/or sensory distortions in the visual, auditory, olfactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or any other substantial subjective changes in cognition, memory, emotion and consciousness."

From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5** -1000 mg of a compound described by formula (I) and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist."

9. NIMH (2021) "Understanding Psychosis" Retrieved 13 May 2021. URL:

https://web.archive.org/web/20210503133654/https://www.nimh.nih .gov/health/publications/understanding-psychosis/

"The word psychosis is used to describe conditions that affect the mind, where there has been some loss of contact with reality."

"Symptoms of psychosis include delusions (false beliefs) and hallucinations (seeing or hearing things that others do not see or hear). Other symptoms include incoherent or nonsense speech and behavior that is inappropriate for the situation. A person in a psychotic episode also may experience depression, anxiety, sleep problems, social withdrawal, lack of motivation, and difficulty functioning overall."

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/ex

periences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 12** "Visualizations began at around 10:30 with crawling carpeting and changes in color hues. I felt as if my head was being detached from the rest of my body. Looking outside I noticed the color of the tree outside our home was leaning closer and closer to the window."

From **paragraph 12** "By around 10:45 - 11:00, the peak is in full swing and I am melting into the floor, **getting very intense**, **hard to see**, **my visual field is sideways and standing up straight becomes hard**. Wow, this is really good acid. **Maybe too good**, **I thought**, **this is only the beginning**, **time to cut this short**."

From **paragraph 13** "At 11:30 (or thereabouts) I consumed approx. 66mg of the Quetiapine."

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit **cutting the LSD short**) from the psychedelic aspect of my trip using the Seroquel, **I would recommend it to anyone, at least to have as part of a psychedelic crisis kit.**"

7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: <u>https://web.archive.org/web/20200928082744/https://www.psyched</u> <u>elicpassage.com/psychedelic-dosage-guide-how-much-of-each-</u> <u>substance-to-take/</u>

	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: 50 –
	150 μ g (micrograms) per individual, 200+ μ g in highly supportive
	settingsthe most common form of LSD comes on blotter paper,
	which is an absorbent paper soaked in a solution of LSD. An
	average sheet of blotter paper has about 100 uniform tabs
	containing about 100 µg per tab."
	4 GUZMAN (2016) "Mechanism of Action of Ouetianine" URL:
	https://psychopharmacologyinstitute.com/publication/mechanism-
	of-action-of-quetiapine-2109
	From paragraph 5 "Quetiapine has antagonist actions at 5-
	HT2A receptors, one of the key properties of second-generation
	antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine
	has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
0.7	
37. The method of	1. Int'l Pat. Doc. No. WO/2019/081/64 "COMBINATION
claim 35, wherein the	AND/OD DSVCHIATRIC DISODDEDS" (Dublished 02 May 2010)
administered in an	AND/OK FSTCHIATRIC DISORDERS (Fublished 02 May 2019)
amount chosen from	From claim 1 "A pharmaceutical combination product
the group consisting of	comprising: compound described by the following formula (I):
0.01-1 mg LSD, 10-50	
mg psilocybin, 100-800	
mg mescaline, 20-100	R _a D
mg DMT, 0.1-5 mg	13 13 13 14 15 16 16
DOI, and 0.1-5 mg	
DOB.	
	$(') \qquad R_2$
	IN IN
	н
	wherein R1 is selected from the group consisting of methyl, ethyl,
	n-propyr, anyr and isopropyr;
	wherein R2 is selected from the group consisting of methyl.
	n-propyl, allyl and isopropyl;
	wherein R3 is selected from the group consisting of hydrogen,
	methoxy, methyl, hydroxy and a halogen; and

wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;
wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and
(ii) a 5-HT2A receptor antagonist;
for use as a medicament."
From claim 3 "The combination product for use according to anyone of claims 1 -2 wherein the compound described by formula (I) is selected from the group consisting of N,N- dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N- diethyltryptamine, N,N-dipropyltryptamine and N,N- diisopropyltryptamine."
From claim 4 "The combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, Pimavanserin , Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK- 215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150."
From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
From page 14 "The terms "hallucinogenic side effects" and "psychedelic side effects" are used in the present application interchangeably to refer to unwanted and/or unintended secondary effects caused by the administration of a medicament to an individual resulting in subjective experiences being qualitatively different from those of ordinary consciousness. These experiences can include derealization, depersonalization, hallucinations and/or sensory distortions in the visual, auditory,
offactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or any other substantial

subjective char consciousness.'	nges in cogniti ,	on, r	nemory, emotion	and
From page 29 " is administered A dosage of the a compound de HT2A receptor	In a preferred of at least two tin combination p escribed by for antagonist."	embo nes, j produ r mu l	odiment, the combi preferably more that let can comprise 0. a (I) and/or 0.5 - 1	nation product an two times. 5 -1000 mg of 000 mg of a 5-
9. NIMH (2021) 2021. URL: https://web.arch .gov/health/pub?) "Understandi ive.org/web/20 lications/under hosis is used to	ng P <u>)210</u> stand	sychosis" Retrieve 503133654/https:// ding-psychosis/ cribe conditions th	d 13 May / <u>www.nimh.nih</u> at affect the
mind, where th "Symptoms of hallucinations" hear). Other sy and behavior th a psychotic epis problems, social functioning over	ere has been s psychosis incl (seeing or hea mptoms inclu hat is inappro ode also may e l withdrawal, l rall."	ome ude ring de in pria exper ack o	loss of contact wi delusions (false be things that others nooherent or nons te for the situation fience depression, a of motivation, and o	th reality." eliefs) and s do not see or eense speech n. A person in anxiety, sleep difficulty
3. PHARMBOY Alcohol" Retrie https://web.arch periences/exp.pl	7 (2013) "Chea ved from 15 O ive.org/web/20 hp?ID=71844	ting ctob	Hofmann - LSD, (er 2013. URL: 015121257/https://	Quetiapine & erowid.org/ex
DOSE: T+ 0.00	1 hit	oral	1.50	(blatter / tab)
T+ 2.00	66 mg	oral	Pharms - Quetianing	(nill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetianine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	([
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	
From paragrap crawling carpeti was being detac noticed the colo and closer to the From paragrap	h 12 "Visualizing and change hed from the r r of the tree ou e window." h 12 "By arou	ation s in est o itside	ns began at around color hues. I felt as f my body. Lookin e our home was lea 0:45 - 11:00, the pe	10:30 with if my head g outside I ning closer eak is in full
swing and I am	melting into th	e flo	or, getting very in	tense, hard to

	see, my visual field is sideways and standing up straight becomes hard. Wow, this is really good acid. Maybe too good, I thought, this is only the beginning, time to cut this short."
	From paragraph 13 "At 11:30 (or thereabouts) I consumed approx. 66mg of the Quetiapine."
	From paragraph 25 "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit. "
	7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: <u>https://web.archive.org/web/20200928082744/https://www.psyched</u> <u>elicpassage.com/psychedelic-dosage-guide-how-much-of-each-</u> <u>substance-to-take/</u>
	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: $50 - 150 \mu g$ (micrograms) per individual, $200 + \mu g$ in highly supportive settingsthe most common form of LSD comes on blotter paper , which is an absorbent paper soaked in a solution of LSD. An average sheet of blotter paper has about 100 uniform tabs containing about 100 μg per tab."
	4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: <u>https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109</u>
	From paragraph 5 "Quetiapine has antagonist actions at 5- HT2A receptors, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
38. The method of	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION
claim 32, wherein the	PRODUCT FOR THE TREATMENT OF NEUROLOGICAL
duration shortening	AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
agent is a SHT2A	Erom aloim 1 "A pharmacoutical combination product
receptor antagomst.	comprising: compound described by the following formula (I):



hallucinations and/or sensory distortions in the visual, auditory, olfactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or any other substantial subjective changes in cognition, memory, emotion and consciousness."

9. NIMH (2021) "Understanding Psychosis" Retrieved 13 May 2021. URL:

https://web.archive.org/web/20210503133654/https://www.nimh.nih .gov/health/publications/understanding-psychosis/

"The word psychosis is used to describe conditions that affect the mind, where there has been some loss of contact with reality."

"Symptoms of psychosis include delusions (false beliefs) and hallucinations (seeing or hearing things that others do not see or hear). Other symptoms include incoherent or nonsense speech and behavior that is inappropriate for the situation. A person in a psychotic episode also may experience depression, anxiety, sleep problems, social withdrawal, lack of motivation, and difficulty functioning overall."

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL:

https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 12** "Visualizations began at around 10:30 with crawling carpeting and changes in color hues. I felt as if my head was being detached from the rest of my body. Looking outside I noticed the color of the tree outside our home was leaning closer and closer to the window."

From **paragraph 12** "By around 10:45 - 11:00, the peak is in full swing and I am melting into the floor, **getting very intense**, **hard to see**, **my visual field is sideways and standing up straight becomes hard**. Wow, this is really good acid. **Maybe too good**, I **thought**, **this is only the beginning**, **time to cut this short**."

	From paragraph 13 "At 11:30 (or thereabouts) I consumed approx. 66mg of the Quetiapine."
	From paragraph 25 "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit. "
	7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: <u>https://web.archive.org/web/20200928082744/https://www.psyched</u> <u>elicpassage.com/psychedelic-dosage-guide-how-much-of-each-</u> <u>substance-to-take/</u>
	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: $50 - 150 \mu g$ (micrograms) per individual, $200 + \mu g$ in highly supportive settingsthe most common form of LSD comes on blotter paper , which is an absorbent paper soaked in a solution of LSD. An average sheet of blotter paper has about 100 uniform tabs containing about 100 μg per tab."
	4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: <u>https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109</u>
	From paragraph 5 " Quetiapine has antagonist actions at 5- HT2A receptors , one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
39. The method of claim 38, wherein the duration shortening	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
the group consisting of pimavanserin, salts thereof, analogs thereof, and homologs thereof.	From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):



	Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150."
	From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
	From page 14 "The terms "hallucinogenic side effects" and "psychedelic side effects" are used in the present application interchangeably to refer to unwanted and/or unintended secondary effects caused by the administration of a medicament to an individual resulting in subjective experiences being qualitatively different from those of ordinary consciousness. These experiences can include derealization, depersonalization, hallucinations and/or sensory distortions in the visual, auditory, olfactory, tactile, proprioceptive and/or interoceptive spheres and/or any other perceptual modifications, and/or any other substantial subjective changes in cognition, memory, emotion and consciousness."
40. The method of claim 39, wherein the pimavanserin is administered in an	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
amount of 1-100 mg.	From claim 1 "A pharmaceutical combination product comprising: compound described by the following formula (I):
	$\begin{array}{c} R_3 \\ R_4 \\ R_5 \\ R_5 \\ R_6 \\ R_7 \\ R_7 \\ R_2 \\ R_7 \\ R_2 \\ R_5 \\ R_7 \\ R_2 \\ R_1 \\ R_2 \\ R_1 \\ R_1 \\ R_2 \\ R_1 \\ R_2 \\ R_1 \\ R_2 \\ R_1 \\ R_2 \\ R_1 \\ R_1 \\ R_2 \\ R_1 \\$

wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;
wherein R3 is selected from the group consisting of hydrogen,
methoxy, methyl, hydroxy and a halogen; and
wherein R4 is selected from the group consisting of hydrogen,
hydroxy, phosphoryloxy and acetoxy;
wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and
(ii) a 5-HT2A receptor antagonist;
for use as a medicament."
From claim 4 "The combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, Pimavanserin , Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK- 215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150."
From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects
caused by a compound described by formula (1).
From page 14 "The terms "hallucinogenic side effects" and
interchangeably to refer to unwanted and/or unintended
secondary effects caused by the administration of a medicament to
an individual resulting in subjective experiences being
qualitatively different from those of ordinary consciousness.
hallucinations and/or sensory distortions in the visual. auditory.
olfactory, tactile, proprioceptive and/or interoceptive spheres and/or
any other perceptual modifications, and/or any other substantial
subjective changes in cognition, memory, emotion and
consciousness."

	From page 29 "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise 0.5 -1000 mg of a compound described by formula (I) and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist ."
	8. FDA (2016) "NUPLAZID (PIMAVANSERIN): HIGHLIGHTS OF PRESCRIBING INFORMATION" URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318 lbl.pdf
	From page 1 "DOSAGE AND ADMINISTRATION: Recommended dose is 34 mg , taken orally as two 17 mg tablets once daily, without titration.
41. A method of stopping psychosis due to a substance or disease, including the steps of: administering a duration shortening agent to the individual caused by a substance or disease other than Parkinson's disease or schizophrenia; and stopping psychosis caused by the substance or disease.	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From claim 2 "A pharmaceutical combination product comprising: compound described by the following formula (I): $R_{3} \qquad R_{4} \qquad R_{5} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{5} \qquad R_{5} \qquad R_{1} \qquad R_{2} \qquad R_{5} \qquad R_{5$
	wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;wherein R2 is selected from the group consisting of methyl, ethyl,
	n-propyl, allyl and isopropyl; wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;
wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and
(ii) a 5-HT2A receptor antagonist;
for use in the treatment and/or prevention of psychiatric and/or neurological disorders."
From claim 9 "The combination product according to anyone of claims 2-8 for use in the treatment and/or prevention of a disorder selected from the group consisting of acquired brain injury, ataxia, brain tumor, dementia, dystonia, epilepsy, functional and dissociative neurological symptoms, meningitis, motor neuron disease, multiple sclerosis, muscular dystrophy, myalgic encephalomyelitis, Parkinson's disease, progressive supranuclear palsy, Huntington's disease, Alzheimer's disease, fronto-temporal dementia, vascular dementia, cognitive decline associated with aging, spina bifida, hydrocephalus, spinal injury, stroke, Tourette syndrome, transverse myelitis, panic disorder, agoraphobia, social anxiety disorder, generalized anxiety disorder, bipolar disorder, depression, anorexia nervosa, binge eating disorder, bulimia nervosa, psychosis , schizophrenia, substance addiction and personality disorders."
2. VALERIANI (2015) "Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms" Human Psychopharmacology: Clinical and Experimental. 30:249-254.
From page 250 "In most cases, users reported here to ingest olanzapine at relatively small dosages, usually ranging from 5 to 10 mg once a day for just a few days as a "terminator"/"modulator" of unwanted NPS psychedelic effects."
From page 251 "Most online reports about olanzapine were here related to its use as a short-term, self-prescribed treatment for the psychedelic crises/"bad trips." Symptoms of psychedelic crises usually last a few hours, depending on the drug taken and dose ingested (Mangot, 2013). Indeed, SC's effects may last 1–4 h

(Hoyte et al., 2012); tryptamines' effects 2–6 h (Hallock et al., 2013); lysergic acid diethylamide [LSD] 6–14 h (Krebs and Johansen, 2013); and mescaline 8–16 h (Trachsel, 2012)."

From **page 251** "There are already published data showing the effectiveness of olanzapine and, in general, of second-generation antipsychotics (SGA), as first-line treatments in psychotic disorders induced by drugs such as cannabis (Bersani et al., 2002a, 2002b; Sevy et al., 2011) and cocaine (Testa et al., 2013). Compared with first-generation antipsychotics (FGA), SGA may present with some advantages while treating drug-induced psychosis, including the following: (i) SGA induce fewer/no extrapyramidal symptoms (Ohno et al., 2013); (ii) SGA quickly dissociate from D2 receptors, unlike FGA/haloperidol, and hence may seem to be less associated with dysphoria and interference with drug reward anticipation/craving (Juckel et al., 2006); (iii) SGA seem more effective in the treatment of negative symptoms (Buchanan et al., 2005), alter positively mood (McIntyre et al., 2004), and have a positive impact on cognition (Bersani et al., 2011); and (iv) SGA act as antagonists of 5HT2A receptor, which is the main target of most hallucinogenic drugs (Potvin et al., 2003). From this point of view, both clozapine and olanzapine may present with a distinct advantage in reducing drug-induced psychotic symptoms (Murthy and Chand, 2012).

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 12** "Visualizations began at around 10:30 with crawling carpeting and changes in color hues. I felt as if my head was being detached from the rest of my body. Looking outside I noticed the color of the tree outside our home was leaning closer and closer to the window."

From **paragraph 12** "By around 10:45 - 11:00, the peak is in full swing and I am melting into the floor, **getting very intense**, **hard to see**, **my visual field is sideways and standing up straight**

	becomes hard . Wow, this is really good acid. Maybe too good , I thought, this is only the beginning, time to cut this short ."
	From paragraph 13 "At 11:30 (or thereabouts) I consumed approx. 66mg of the Quetiapine."
	From paragraph 25 "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit. "
	7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: <u>https://web.archive.org/web/20200928082744/https://www.psyched</u> <u>elicpassage.com/psychedelic-dosage-guide-how-much-of-each-</u> <u>substance-to-take/</u>
	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: $50 - 150 \mu g$ (micrograms) per individual, $200 + \mu g$ in highly supportive settingsthe most common form of LSD comes on blotter paper , which is an absorbent paper soaked in a solution of LSD. An average sheet of blotter paper has about 100 uniform tabs containing about 100 μg per tab."
	4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: <u>https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109</u>
	From paragraph 5 " Quetiapine has antagonist actions at 5- HT2A receptors , one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
42. The method of claim 41, wherein the disease is chosen from the group consisting of	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
bipolar disorder, severe depression, severe stress, severe anxiety, HIV, AIDS, malaria, syphilis, hypoglycemia, lupus, multiple sclerosis, and brain tumors.	From claim 2 "A pharmaceutical combination product comprising: compound described by the following formula (I):



	anxiety disorder, phobias, post-traumatic stress disorder, obsessive compulsive disorder, generalized anxiety disorder , bipolar disorder , depression , anorexia nervosa, binge eating disorder, bulimia nervosa, psychosis , schizophrenia, substance addiction and personality disorders."
43. The method of claim 41, wherein the substance is chosen	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
consisting of cocaine, cannabis, alcohol, muscle relaxants, antihistamines,	From claim 2 "A pharmaceutical combination product comprising: compound described by the following formula (I):
antidepressants, cardiovascular medications, antihypertensive medications, analgesics, anticonvulsants, anti- Parkinson medications, chemotherapy agents, corticosteroids, and psychedelics.	R_{3} R_{4} R_{5} R_{7} R_{1} R_{2}
	wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;
	wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;
	wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and
	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;
	wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and
	(ii) a 5-HT2A receptor antagonist;

for use in the treatment and/or prevention of psychiatric and/or neurological disorders."

From claim 9 "The combination product according to anyone of claims 2-8 for use in the treatment and/or prevention of a disorder selected from the group consisting of acquired brain injury, ataxia, brain tumor, dementia, dystonia, epilepsy, functional and dissociative neurological symptoms, meningitis, motor neuron disease, multiple sclerosis, muscular dystrophy, myalgic encephalomyelitis, Parkinson's disease, progressive supranuclear palsy, Huntington's disease, Alzheimer's disease, fronto-temporal dementia, vascular dementia, cognitive decline associated with aging, spina bifida, hydrocephalus, spinal injury, stroke, Tourette syndrome, transverse myelitis, panic disorder, agoraphobia, social anxiety disorder, phobias, post-traumatic stress disorder, obsessive compulsive disorder, generalized anxiety disorder, bipolar disorder, depression, anorexia nervosa, binge eating disorder, bulimia nervosa, psychosis, schizophrenia, substance addiction and personality disorders."

2. VALERIANI (2015) "Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms" Human Psychopharmacology: Clinical and Experimental. 30:249-254.

From page 250 "In most cases, users reported here to ingest olanzapine at relatively small dosages, usually ranging from 5 to 10 mg once a day for just a few days as a "terminator"/"modulator" of unwanted NPS psychedelic effects."

From **page 251** "Most online reports about olanzapine were here related to its use as a short-term, self-prescribed treatment for the psychedelic crises/"bad trips." Symptoms of psychedelic crises usually last a few hours, depending on the drug taken and dose ingested (Mangot, 2013). Indeed, SC's effects may last 1–4 h (Hoyte et al., 2012); tryptamines' effects 2–6 h (Hallock et al., 2013); lysergic acid diethylamide [LSD] 6–14 h (Krebs and Johansen, 2013); and mescaline 8–16 h (Trachsel, 2012)."

From **page 251** "There are already published data showing the effectiveness of olanzapine and, in general, of second-generation antipsychotics (SGA), as first-line treatments in psychotic disorders induced by drugs such as cannabis (Bersani et al., 2002a, 2002b; Sevy et al., 2011) and cocaine (Testa et al., 2013). Compared with

first-generation antipsychotics (FGA), SGA may present with some advantages while treating drug-induced psychosis, including the following: (i) SGA induce fewer/no extrapyramidal symptoms (Ohno et al., 2013); (ii) SGA quickly dissociate from D2 receptors, unlike FGA/haloperidol, and hence may seem to be less associated with dysphoria and interference with drug reward anticipation/craving (Juckel et al., 2006); (iii) SGA seem more effective in the treatment of negative symptoms (Buchanan et al., 2005), alter positively mood (McIntyre et al., 2004), and have a positive impact on cognition (Bersani et al., 2011); and (iv) **SGA act as antagonists of 5HT2A receptor, which is the main target of most hallucinogenic drugs** (Potvin et al., 2003). From this point of view, **both clozapine and olanzapine may present with a distinct advantage in reducing drug-induced psychotic symptoms** (Murthy and Chand, 2012).

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 12** "Visualizations began at around 10:30 with crawling carpeting and changes in color hues. I felt as if my head was being detached from the rest of my body. Looking outside I noticed the color of the tree outside our home was leaning closer and closer to the window."

From **paragraph 12** "By around 10:45 - 11:00, the peak is in full swing and I am melting into the floor, **getting very intense**, **hard to see**, **my visual field is sideways and standing up straight becomes hard**. Wow, this is really good acid. **Maybe too good**, **I thought**, **this is only the beginning**, **time to cut this short**."

From **paragraph 13** "At 11:30 (or thereabouts) I consumed approx. 66mg of the Quetiapine."

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit **cutting the LSD short**) from the psychedelic

	aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit."
	7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: <u>https://web.archive.org/web/20200928082744/https://www.psyched</u> <u>elicpassage.com/psychedelic-dosage-guide-how-much-of-each-</u> <u>substance-to-take/</u>
	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: $50 - 150 \mu g$ (micrograms) per individual, $200 + \mu g$ in highly supportive settingsthe most common form of LSD comes on blotter paper , which is an absorbent paper soaked in a solution of LSD. An average sheet of blotter paper has about 100 uniform tabs containing about 100 μg per tab."
	4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: <u>https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109</u>
	From paragraph 5 " Quetiapine has antagonist actions at 5- HT2A receptors , one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
44. The method of claim 41, wherein the duration shortening agent is administered 1	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
minute to 24 hours after administering the psychedelic drug.	From claim 2 "A pharmaceutical combination product comprising: compound described by the following formula (I):



anxiety disorder, phobias, post-traumatic stress disorder, obsessive compulsive disorder, generalized anxiety disorder, bipolar disorder, depression, anorexia nervosa, binge eating disorder, bulimia nervosa, **psychosis**, schizophrenia, substance addiction and personality disorders."

From **page 32** "In a preferred embodiment, a compound described by formula (I) may be administered to an individual who is already being administered a 5-HT2A receptor antagonist and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders. Conversely, in an alternative embodiment, a 5-HT2A receptor antagonist may be administered to an individual who is already being administered a compound described by formula (I) and who is suffering from one or more psychiatric and/or neurological disorders and/or who is at risk of suffering from one or more psychiatric and/or neurological disorders."

2. VALERIANI (2015) "Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms" Human Psychopharmacology: Clinical and Experimental. 30:249-254.

From page 250 "In most cases, users reported here to ingest olanzapine at relatively small dosages, usually ranging from 5 to 10 mg once a day for just a few days as a "terminator"/"modulator" of unwanted NPS psychedelic effects."

From **page 251** "Most online reports about olanzapine were here related to its use as a short-term, self-prescribed treatment for the psychedelic crises/"bad trips." Symptoms of psychedelic crises usually last a few hours, depending on the drug taken and dose ingested (Mangot, 2013). Indeed, SC's effects may last 1–4 h (Hoyte et al., 2012); tryptamines' effects 2–6 h (Hallock et al., 2013); lysergic acid diethylamide [LSD] 6–14 h (Krebs and Johansen, 2013); and mescaline 8–16 h (Trachsel, 2012)."

From **page 251** "There are already published data showing the effectiveness of olanzapine and, in general, of second-generation antipsychotics (SGA), as first-line treatments in psychotic disorders induced by drugs such as cannabis (Bersani et al., 2002a, 2002b; Sevy et al., 2011) and cocaine (Testa et al., 2013). Compared with first-generation antipsychotics (FGA), SGA may present with some

advantages while treating drug-induced psychosis, including the following: (i) SGA induce fewer/no extrapyramidal symptoms (Ohno et al., 2013); (ii) SGA quickly dissociate from D2 receptors, unlike FGA/haloperidol, and hence may seem to be less associated with dysphoria and interference with drug reward anticipation/craving (Juckel et al., 2006); (iii) SGA seem more effective in the treatment of negative symptoms (Buchanan et al., 2005), alter positively mood (McIntyre et al., 2004), and have a positive impact on cognition (Bersani et al., 2011); and (iv) SGA act as antagonists of 5HT2A receptor, which is the main target of most hallucinogenic drugs (Potvin et al., 2003). From this point of view, both clozapine and olanzapine may present with a distinct advantage in reducing drug-induced psychotic symptoms (Murthy and Chand, 2012)."

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit."

7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: <u>https://web.archive.org/web/20200928082744/https://www.psyched</u> <u>elicpassage.com/psychedelic-dosage-guide-how-much-of-each-</u> <u>substance-to-take/</u>

"Lysergic Acid Diethylamide (LSD): Recommended Dosage: $50 - 150 \mu g$ (micrograms) per individual, $200 + \mu g$ in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 \mu g per tab."**

	 4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: <u>https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109</u> From paragraph 5 "Quetiapine has antagonist actions at 5- HT2A receptors, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
45. The method of claim 41, wherein the psychedelic drug is a 5HT2A agonist chosen from the group consisting of LSD, psilocybin, psilocin, mescaline, 5-methoxy- N,N- dimethyltryptamine (5- MeO-DMT), dimethyltryptamine (DMT), 2,5-dimethoxy- 4-iodoamphetamine (DOI), 2,5-dimethoxy- 4-bromoamphetamie (DOB), salts thereof, tartrates thereof, solvates thereof, isomers thereof, deuterated forms thereof, analogs	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From claim 2 "A pharmaceutical combination product comprising: compound described by the following formula (I):
	$R^{5} R^{3} N R_{2}$
thereof, and homologues thereof.	wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;
	wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;
	wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and
	wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;
	wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and

(ii) a 5-HT2A receptor antagonist;

for use in the treatment and/or prevention of psychiatric and/or neurological disorders."

From claim 3 "The combination product for use according to anyone of claims 1 -2 wherein the compound described by formula (I) is selected from the group consisting of N,Ndimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,Ndiethyltryptamine, N,N-dipropyltryptamine and N,Ndiisopropyltryptamine."

From claim 4 "The combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150."

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: <u>https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844</u>

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit."

	7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each
	Substance to Take" Retrieved 28 September 2020. URL:
	https://web.arcmve.org/web/20200928082744/https://www.psyched
	encpassage.com/psychedenc-dosage-guide-now-much-of-each-
	<u>substance-to-take</u>
	"Lysergic Acid Diethylamide (LSD): Recommended Dosage: $50 - 150 \mu g$ (micrograms) per individual, $200 + \mu g$ in highly supportive settingsthe most common form of LSD comes on blotter paper , which is an absorbent paper soaked in a solution of LSD. An average sheet of blotter paper has about 100 uniform tabs containing about 100 μg per tab."
	4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: <u>https://psychopharmacologyinstitute.com/publication/mechanism-of-action-of-quetiapine-2109</u>
	From paragraph 5 " Quetiapine has antagonist actions at 5- HT2A receptors , one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
46. The method of	1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION
claim 41, wherein the	PRODUCT FOR THE TREATMENT OF NEUROLOGICAL
psychedelic drug is	AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)
administered in an amount that provides an effect for at least 2 hours.	From claim 2 "A pharmaceutical combination product comprising: compound described by the following formula (I):
	R_{3} R_{4} R_{5} R_{7} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2} R_{1} R_{2}
	wherein R1 is selected from the group consisting of methyl, ethyl,
	n-propyl, allyl and isopropyl;

wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;
wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and
wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;
wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); and
(ii) a 5-HT2A receptor antagonist;
for use in the treatment and/or prevention of psychiatric and/or neurological disorders."
From claim 3 "The combination product for use according to anyone of claims 1 -2 wherein the compound described by formula (I) is selected from the group consisting of N,N- dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,N- diethyltryptamine, N,N-dipropyltryptamine and N,N- diisopropyltryptamine."
From claim 4 "The combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, Pimavanserin , Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK- 215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150."
From claim 9 "The combination product according to anyone of claims 2-8 for use in the treatment and/or prevention of a disorder selected from the group consisting of acquired brain injury, ataxia, brain tumor, dementia, dystonia, epilepsy, functional and dissociative neurological symptoms, meningitis, motor neuron disease, multiple sclerosis, muscular dystrophy, myalgic encephalomyelitis, Parkinson's disease, progressive supranuclear palsy, Huntington's disease, Alzheimer's disease, fronto-temporal

dementia, vascular dementia, cognitive decline associated with aging, spina bifida, hydrocephalus, spinal injury, stroke, Tourette syndrome, transverse myelitis, panic disorder, agoraphobia, social anxiety disorder, phobias, post-traumatic stress disorder, obsessive compulsive disorder, generalized anxiety disorder, bipolar disorder, depression, anorexia nervosa, binge eating disorder, bulimia nervosa, **psychosis**, schizophrenia, substance addiction and personality disorders."

From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5 -1000 mg of a compound described by formula (I)** and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist."

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit."

7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: <u>https://web.archive.org/web/20200928082744/https://www.psyched</u> <u>elicpassage.com/psychedelic-dosage-guide-how-much-of-each-</u> <u>substance-to-take/</u>

"Lysergic Acid Diethylamide (LSD): Recommended Dosage: $50 - 150 \mu g$ (micrograms) per individual, $200 + \mu g$ in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 \mu g per tab."**



(ii) a 5-HT2A receptor antagonist;

for use in the treatment and/or prevention of psychiatric and/or neurological disorders."

From claim 3 "The combination product for use according to anyone of claims 1 -2 wherein the compound described by formula (I) is selected from the group consisting of N,Ndimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, N,Ndiethyltryptamine, N,N-dipropyltryptamine and N,Ndiisopropyltryptamine."

From claim 4 "The combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150."

From claim 9 "The combination product according to anyone of claims 2-8 for use in the treatment and/or prevention of a disorder selected from the group consisting of acquired brain injury, ataxia, brain tumor, dementia, dystonia, epilepsy, functional and dissociative neurological symptoms, meningitis, motor neuron disease, multiple sclerosis, muscular dystrophy, myalgic encephalomyelitis, Parkinson's disease, progressive supranuclear palsy, Huntington's disease, Alzheimer's disease, fronto-temporal dementia, vascular dementia, cognitive decline associated with aging, spina bifida, hydrocephalus, spinal injury, stroke, Tourette syndrome, transverse myelitis, panic disorder, agoraphobia, social anxiety disorder, phobias, post-traumatic stress disorder, obsessive compulsive disorder, generalized anxiety disorder, bipolar disorder, depression, anorexia nervosa, binge eating disorder, bulimia nervosa, psychosis, schizophrenia, substance addiction and personality disorders."

From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5 -1000 mg of**

a compound described by formula (I) and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist."

3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL: https://web.archive.org/web/20131015121257/https://erowid.org/experiences/exp.php?ID=71844

DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)
T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)
T+ 4:00	200 mg	oral	Pharms - Ibuprofen	
T+ 6:30	1 glass	oral	Alcohol - Beer/Wine	

From **paragraph 25** "Considering how easy and smooth it felt coming down (albeit cutting the LSD short) from the psychedelic aspect of my trip using the Seroquel, I would recommend it to anyone, at least to have as part of a psychedelic crisis kit."

7. LEVICH (2020) "Psychedelic Dosage Guide: How Much of Each Substance to Take" Retrieved 28 September 2020. URL: <u>https://web.archive.org/web/20200928082744/https://www.psyched</u> <u>elicpassage.com/psychedelic-dosage-guide-how-much-of-each-</u> <u>substance-to-take/</u>

"Lysergic Acid Diethylamide (LSD): Recommended Dosage: $50 - 150 \mu g$ (micrograms) per individual, $200 + \mu g$ in highly supportive settings...the most common form of **LSD comes on blotter paper**, which is an absorbent paper soaked in a solution of LSD. **An average sheet of blotter paper has about 100 uniform tabs containing about 100 \mu g per tab."**

4. GUZMAN (2016) "Mechanism of Action of Quetiapine" URL: https://psychopharmacologyinstitute.com/publication/mechanismof-action-of-quetiapine-2109

From **paragraph 5** "**Quetiapine has antagonist actions at 5-HT2A receptors**, one of the key properties of second-generation antipsychotics is that they have a high 5-HT2A/D2 ratio. Quetiapine has higher affinity for 5-HT2A receptors than for D2 receptors [3]."
48. The method of claim 41, wherein the duration shortening agent is a 5HT2A receptor antagonist.

1. Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019)

From claim 2 "A pharmaceutical combination product comprising: compound described by the following formula (I):



wherein R1 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, allyl and isopropyl;

wherein R3 is selected from the group consisting of hydrogen, methoxy, methyl, hydroxy and a halogen; and

wherein R4 is selected from the group consisting of hydrogen, hydroxy, phosphoryloxy and acetoxy;

wherein R5 is selected from the group consisting of deuterium (2H) and protium (1H); **and**

(ii) a 5-HT2A receptor antagonist;

for use in the treatment and/or prevention of psychiatric and/or neurological disorders."

From **claim 3** "The combination product for use according to anyone of claims 1 -2 wherein the compound described by **formula** (I) is selected from the group consisting of N,N**dimethyltryptamine**, **5-methoxy-N,N-dimethyltryptamine**, N,N- diethyltryptamine, N,N-dipropyltryptamine and N,N-diisopropyltryptamine."

From claim 4 "The combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone, Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, **Pimavanserin**, Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK-215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150."

From claim 9 "The combination product according to anyone of claims 2-8 for use in the treatment and/or prevention of a disorder selected from the group consisting of acquired brain injury, ataxia, brain tumor, dementia, dystonia, epilepsy, functional and dissociative neurological symptoms, meningitis, motor neuron disease, multiple sclerosis, muscular dystrophy, myalgic encephalomyelitis, Parkinson's disease, progressive supranuclear palsy, Huntington's disease, Alzheimer's disease, fronto-temporal dementia, vascular dementia, cognitive decline associated with aging, spina bifida, hydrocephalus, spinal injury, stroke, Tourette syndrome, transverse myelitis, panic disorder, agoraphobia, social anxiety disorder, phobias, post-traumatic stress disorder, obsessive compulsive disorder, generalized anxiety disorder, bipolar disorder, depression, anorexia nervosa, binge eating disorder, bulimia nervosa, psychosis, schizophrenia, substance addiction and personality disorders."

From **page 29** "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise **0.5** -1000 mg of a compound described by formula (I) and/or 0.5 - 1000 mg of a 5-HT2A receptor antagonist."

From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."

	3. PHARMBOY (2013) "Cheating Hofmann - LSD, Quetiapine & Alcohol" Retrieved from 15 October 2013. URL:					
	https://web.archive.org/web/20131015121257/https://erowid.org/ex					
	periences/exp.php?ID=71844					
	DOSE: T+ 0:00	1 hit	oral	LSD	(blotter / tab)	
	T+ 2:00	66 mg	oral	Pharms - Quetiapine	(pill / tablet)	
	T+ 3:00	33 mg	oral	Pharms - Quetiapine	(pill / tablet)	
	T+ 4:00	200 mg	oral	Pharms - Ibuprofen		
	T+ 6:30	1 glass	oral	Alcohol - Beer/Wine		
	From paragrap coming down (a aspect of my tr anyone, at least	h 25 "Conside Ilbeit cutting t ip using the S to have as part	ering he L eroq t of a	how easy and smo SD short) from th uel , I would recom psychedelic crisis	oth it felt ne psychedelic nmend it to kit."	
	7. LEVICH (20) Substance to Ta https://web.arch elicpassage.com substance-to-tak	20) "Psychede ke" Retrieved <u>ive.org/web/20</u> <u>/psychedelic-c</u> <u>ke/</u>	lic D 28 S <u>0200</u> losag	osage Guide: How eptember 2020. UI 928082744/https:// ge-guide-how-mucl	Y Much of Each RL: <u>/www.psyched</u> <u>h-of-each-</u>	
	"Lysergic Acid Diethylamide (LSD): Recommended Dosage 150 μ g (micrograms) per individual, 200+ μ g in highly supp settingsthe most common form of LSD comes on blotter which is an absorbent paper soaked in a solution of LSD. An average sheet of blotter paper has about 100 uniform tak containing about 100 μg per tab ."			Dosage: 50 – y supportive lotter paper, SD. An rm tabs		
	4. GUZMAN (2 https://psychoph of-action-of-que	2016) "Mechar narmacologyin etiapine-2109	ism <u>stitut</u>	of Action of Quetian o	apine" URL: / <u>mechanism-</u>	
	From paragrap HT2A receptor antipsychotics is has higher affine	h 5 "Quetiapi rs, one of the k s that they hav ity for 5-HT2A	ine h iey pi e a h i reco	as antagonist actions of second agenties of second agent 5-HT2A/D2 rates than for D2	ons at 5- -generation tio. Quetiapine receptors [3]."	
49. The method of claim 48, wherein the duration shortening agent is chosen from	1. Int'l Pat. Doc PRODUCT FOI AND/OR PSYC	. No. WO/201 R THE TREA CHIATRIC DIS	9/08 FME SOR	1764 "COMBINA" NT OF NEUROL(DERS" (Published	TION OGICAL 02 May 2019)	
the group consisting of pimavanserin, salts	From claim 2 ". comprising: co	A pharmaceu mpound desc	tical ribed	combination proc l by the following	luct formula (I):	

thereof, analogs thereof, and homologs thereof.



diisopropyltryptamine."

From claim 4 "The combination product for use according to any one of claims 1 -3 wherein the 5-HT2A receptor antagonist is selected from the group consisting of Methiothepin, Ritanserin, Ketanserin, Flibanserin, Methysergide, Trazodone, Nefazodone,

	Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, Pimavanserin , Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK- 215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150."
	From claim 9 "The combination product according to anyone of claims 2-8 for use in the treatment and/or prevention of a disorder selected from the group consisting of acquired brain injury, ataxia, brain tumor, dementia, dystonia, epilepsy, functional and dissociative neurological symptoms, meningitis, motor neuron disease, multiple sclerosis, muscular dystrophy, myalgic encephalomyelitis, Parkinson's disease, progressive supranuclear palsy, Huntington's disease, Alzheimer's disease, fronto-temporal dementia, vascular dementia, cognitive decline associated with aging, spina bifida, hydrocephalus, spinal injury, stroke, Tourette syndrome, transverse myelitis, panic disorder, agoraphobia, social anxiety disorder, phobias, post-traumatic stress disorder, obsessive compulsive disorder, generalized anxiety disorder, bulimia nervosa, psychosis , schizophrenia, substance addiction and personality disorders."
	From page 29 "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise 0.5 -1000 mg of a compound described by formula (I) and/or 0.5 - 1000 mg of a 5- HT2A receptor antagonist."
	From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
50. The method of claim 49, wherein the pimavanserin is administered in an amount of 1-100 mg.	 Int'l Pat. Doc. No. WO/2019/081764 "COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS" (Published 02 May 2019) From claim 2 "A pharmaceutical combination product comprising: compound described by the following formula (I):



Cinitapride, Cyproheptadine, Brexpiprazole, Cariprazine, Agomelatine, Pimavanserin , Eplivanserin, Volinanserin, Altanserin, Setoperone, LY-367,265, 1 -(1 -Naphthyl)piperazine, SB 206553, Pirenperone, SB-215505, Metergoline, Deramciclane, Amperozide, Glemanserin, 5-MeO-NBpBrT, Adatanserin, AM DA, Cinanserin, Fananserin, Iferanserin, AC-90179, LY86057, GSK- 215083, Cyamemazine, Mesulergine, BF-1, LY215840, Sergolexole, Spiramide, LY53857, Amesergide, LY108742, Pipamperone, LY314228 and 5-I- 91 150."
From claim 9 "The combination product according to anyone of claims 2-8 for use in the treatment and/or prevention of a disorder selected from the group consisting of acquired brain injury, ataxia, brain tumor, dementia, dystonia, epilepsy, functional and dissociative neurological symptoms, meningitis, motor neuron disease, multiple sclerosis, muscular dystrophy, myalgic encephalomyelitis, Parkinson's disease, progressive supranuclear palsy, Huntington's disease, Alzheimer's disease, fronto-temporal dementia, vascular dementia, cognitive decline associated with aging, spina bifida, hydrocephalus, spinal injury, stroke, Tourette syndrome, transverse myelitis, panic disorder, agoraphobia, social anxiety disorder, phobias, post-traumatic stress disorder, obsessive compulsive disorder, generalized anxiety disorder, bulimia nervosa, psychosis , schizophrenia, substance addiction and personality disorders."
From page 29 "In a preferred embodiment, the combination product is administered at least two times, preferably more than two times. A dosage of the combination product can comprise 0 .5 -1000 mg of a compound described by formula (I) and/or 0.5 - 1000 mg of a 5- HT2A receptor antagonist ."
From page 32 "In a preferred embodiment, the 5-HT2A receptor antagonist present in the combination product alleviates and/or eliminates the hallucinogenic and/or psychedelic side effects caused by a compound described by formula (I)."
8. FDA (2016) "NUPLAZID (PIMAVANSERIN): HIGHLIGHTS OF PRESCRIBING INFORMATION" URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318 lbl.pdf
From page 1 "DOSAGE AND ADMINISTRATION: Recommended dose is 34 mg , taken orally as two 17 mg tablets once daily, without titration.

Electronic Acknowledgement Receipt				
EFS ID:	47816445			
Application Number:	17833829			
International Application Number:				
Confirmation Number:	4702			
Title of Invention:	CONTROLLING EFFECTS AFTER 5HT2A AGONISTS ADMINISTRATION			
First Named Inventor/Applicant Name:	Daniel R. KARLIN			
Customer Number:	48924			
Filer:	Shahin Shams			
Filer Authorized By:				
Attorney Docket Number:	0614.00142			
Receipt Date:	10-APR-2023			
Filing Date:	06-JUN-2022			
Time Stamp:	15:02:50			
Application Type:				

Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	\$72
RAM confirmation Number	E202340F02448302
Deposit Account	
Authorized User	
The Directory (the LICDTO is hereby a thread of the shares	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
		Concise-description-generated. pdf	48337	no	9
1	Concise Description of Relevance		a11054f8b61af065fd19149cb5822652b4d0 46ea		
Warnings:					
Information:					
		Third-party-preissuance- submission.pdf	71269		
2	Third-Party Submission Under 37 CFR 1.290		8b4afb/cf1a587e41f0ffb54278721c4eb21b 6c2	no	5
Warnings:			••		
Information:					
			23721	no	1
3	Request for Notification of Non- compliant Third-Party Submission	Third-party-notification- request.pdf	2aa887b2b082cb0560bb7c9cd3218e0747 77990b		
Warnings:		1			
Information:					
			566867	no	116
4	Concise Description of Relevance	US20220395499ClaimsChartCo mp.pdf	30ce2233a1454e4957822ad164c72219908 1af2a		
Warnings:					
Information:		1			
		1_	701437		
5	Evidence of Publication	WO2019081764AsFiledComp. pdf	48868c73c78727322f643830337480839fa1 de01	no	64
Warnings:					
Information:		-			
			160452	no	6
6	Evidence of Publication	2-Valeriani2015.pdf	685f6afcdc5f2ecfa41e2009ff53d2f7c0653b 6e		
Warnings:		·	· ·		
Information:					

7	Evidence of Publication	3-PHARMBOYComp.pdf	500446 c6727faad88b8562cd75c746c56417f4d25b 272b	no	3
Warnings:					
Information:		I	1		1
			639874		
8	Evidence of Publication	4-GUZMAN.pdf	651c6f5c043f6329d3a7028526a321d1bb7 61977	no	4
Warnings:		1	1		
Information:					
			184780	no	
9	Evidence of Publication	5-MAHATMAGANJA.pdf	27dbd33e2aff81f890621be12fce8881c985 b819		1
Warnings:					
Information:					
			863469	no	5
10	Evidence of Publication	6-BIGWOODComp5.pdf	c36dc3497a1bce7e474ca23504fb5a6e64e 290ab		
Warnings:		1	•		
Information:					
			13674060		
11	Evidence of Publication	7-LEVICH.pdf	4753cbc77f3f241156d2f2bca2cb5f7fc070af a2	no	16
Warnings:					
Information:					
12	Evidence of Publication	8-NUPLAZIDComp.pdf	277818	no	1
			bb9a382bcae36a65ef9942e78ddefc20e7aa 5b2a		
Warnings:		·	·		
Information:					
			370938		
13	Evidence of Publication	9-NIMH.pdf	503b3c5af78e792e0032f9f6a974ee90e7fc0 8fb	no	3
Warnings:		·	·		
Information:					

14	Fee Worksheet (SB06)	fee-info.pdf	37327 23d2ec2d48fc23703c6c88719fe1a0b6029f a763	no	2	
Warnings:	4	1	ł			
Information	:					
		Total Files Size (in bytes)	: 18	120795		
This Acknow characterize Post Card, a If a new app 1.53(b)-(d) a Acknowledg <u>National Sta</u> If a timely su U.S.C. 371 a national sta <u>New Interna</u> If a new inte an internati and of the Ir national sec the applicat	This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. New Applications Under 35 U.S.C. 111 If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. National Stage of an International Application under 35 U.S.C. 371 If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other application Filed with the USPTO as a Receiving Office If a new international Application is being filed and the international application includes the necessary components for a ninternational Application seen a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. New International Application is being filed and the international application includes the necessary components for an international application is being filed and the international application includes the necessary components for an international Application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt w					